MXPA01009502A - Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease - Google Patents
Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated diseaseInfo
- Publication number
- MXPA01009502A MXPA01009502A MXPA/A/2001/009502A MXPA01009502A MXPA01009502A MX PA01009502 A MXPA01009502 A MX PA01009502A MX PA01009502 A MXPA01009502 A MX PA01009502A MX PA01009502 A MXPA01009502 A MX PA01009502A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- formula
- pyrimidinyl
- amino
- group
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 23
- 230000001404 mediated Effects 0.000 title claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 title description 30
- 239000003112 inhibitor Substances 0.000 title description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title description 4
- 229940083082 Pyrimidine derivatives acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- -1 bicyclic compound Chemical class 0.000 claims abstract description 461
- 229910052757 nitrogen Chemical group 0.000 claims abstract description 114
- 150000002148 esters Chemical class 0.000 claims abstract description 58
- 239000001257 hydrogen Substances 0.000 claims abstract description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 53
- 125000005843 halogen group Chemical group 0.000 claims abstract description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 51
- 239000011780 sodium chloride Substances 0.000 claims abstract description 51
- 150000003839 salts Chemical class 0.000 claims abstract description 50
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims abstract description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 31
- 102000004127 Cytokines Human genes 0.000 claims abstract description 20
- 108090000695 Cytokines Proteins 0.000 claims abstract description 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000005842 heteroatoms Chemical group 0.000 claims abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 239000001301 oxygen Substances 0.000 claims abstract description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 200
- 150000001875 compounds Chemical class 0.000 claims description 120
- 125000003545 alkoxy group Chemical group 0.000 claims description 52
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 41
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000002619 bicyclic group Chemical group 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 20
- 230000004927 fusion Effects 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 125000004076 pyridyl group Chemical group 0.000 claims description 17
- HKWZDQXHGWQFAO-UHFFFAOYSA-N N-[3-[(7-aminopyrido[4,3-d]pyrimidin-4-yl)amino]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(NC=2C3=CN=C(N)C=C3N=CN=2)=C1 HKWZDQXHGWQFAO-UHFFFAOYSA-N 0.000 claims description 16
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 16
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 16
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 15
- 125000002541 furyl group Chemical group 0.000 claims description 15
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims description 13
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 12
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 11
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims description 11
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 11
- 125000001589 carboacyl group Chemical group 0.000 claims description 10
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 10
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 10
- 125000001544 thienyl group Chemical group 0.000 claims description 10
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 8
- 125000002971 oxazolyl group Chemical group 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical group CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 7
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- BVJSHQWNXSXIBK-UHFFFAOYSA-N di(ethyl)azanide Chemical group [CH2]C[N-]C[CH2+] BVJSHQWNXSXIBK-UHFFFAOYSA-N 0.000 claims description 7
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 7
- 239000011593 sulfur Chemical group 0.000 claims description 7
- 125000002431 aminoalkoxy group Chemical group 0.000 claims description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 6
- 230000001681 protective Effects 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 238000005804 alkylation reaction Methods 0.000 claims description 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 claims description 4
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 4
- 125000005529 alkyleneoxy group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 4
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
- 125000005702 oxyalkylene group Chemical group 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- 150000003855 acyl compounds Chemical class 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 3
- AHWXWRXRSPGRFA-UHFFFAOYSA-N N-[4-methyl-3-(7H-purin-6-ylamino)phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(NC=2C=3NC=NC=3N=CN=2)C(C)=CC=C1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 AHWXWRXRSPGRFA-UHFFFAOYSA-N 0.000 claims description 2
- LYUCEUFTFTVDDH-UHFFFAOYSA-N N-[4-methyl-3-(pteridin-4-ylamino)phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(NC=2C3=NC=CN=C3N=CN=2)C(C)=CC=C1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 LYUCEUFTFTVDDH-UHFFFAOYSA-N 0.000 claims description 2
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- KETNZVACBVXSAK-UHFFFAOYSA-N N-[4-methyl-3-(pyrido[4,3-d]pyrimidin-4-ylamino)phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(NC=2C3=CN=CC=C3N=CN=2)C(C)=CC=C1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 KETNZVACBVXSAK-UHFFFAOYSA-N 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 25
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 239000005864 Sulphur Chemical group 0.000 abstract 1
- 101710040537 TNF Proteins 0.000 description 38
- 239000000203 mixture Substances 0.000 description 37
- 102100000918 MAPK14 Human genes 0.000 description 19
- 108060001945 CRK Proteins 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 18
- 102100009534 TNF Human genes 0.000 description 17
- 150000002431 hydrogen Chemical group 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 108010002352 Interleukin-1 Proteins 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 239000002609 media Substances 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000004369 Blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 108091000081 Phosphotransferases Proteins 0.000 description 7
- 102000001253 Protein Kinases Human genes 0.000 description 7
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000001963 growth media Substances 0.000 description 7
- 101710004309 p38a Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- 102100012607 MAP2K6 Human genes 0.000 description 6
- 101710027753 MAP2K6 Proteins 0.000 description 6
- 101710038869 MKK6 Proteins 0.000 description 6
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 6
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 150000001448 anilines Chemical class 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004027 cells Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrugs Drugs 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
- 208000006673 Asthma Diseases 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- QUUDAEVLJPIPGJ-UHFFFAOYSA-N N-(3-amino-4-methylphenyl)-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(N)C(C)=CC=C1NC(=O)C1=CC=NC(N2CCOCC2)=C1 QUUDAEVLJPIPGJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 239000007759 RPMI Media 1640 Substances 0.000 description 4
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 4
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 200000000018 inflammatory disease Diseases 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 229940113083 morpholine Drugs 0.000 description 4
- 150000002829 nitrogen Chemical group 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940029284 trichlorofluoromethane Drugs 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229940067606 Lecithin Drugs 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 206010040070 Septic shock Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 201000004681 psoriasis Diseases 0.000 description 3
- 125000002755 pyrazolinyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 2
- HBRAGDYMFAZUBV-UHFFFAOYSA-N 2-chloro-N-(4-methyl-3-nitrophenyl)pyridine-4-carboxamide Chemical compound C1=C([N+]([O-])=O)C(C)=CC=C1NC(=O)C1=CC=NC(Cl)=C1 HBRAGDYMFAZUBV-UHFFFAOYSA-N 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 Aspartame Drugs 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- 210000000845 Cartilage Anatomy 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 208000003067 Myocardial Ischemia Diseases 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229960005322 Streptomycin Drugs 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 229960004793 Sucrose Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 150000001347 alkyl bromides Chemical class 0.000 description 2
- 150000001348 alkyl chlorides Chemical class 0.000 description 2
- 150000001351 alkyl iodides Chemical class 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002456 anti-arthritic Effects 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000001634 furandiyl group Chemical group O1C(=C(C=C1)*)* 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229960000060 monoclonal antibodies Drugs 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 125000005633 phthalidyl group Chemical group 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001184 potassium carbonate Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 125000004665 trialkylsilyl group Chemical group 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- FIWSRSRCWYARAJ-SQOFCNSWSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FIWSRSRCWYARAJ-SQOFCNSWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- XKEBMWRWBWRQAO-UHFFFAOYSA-N 1H-pyrido[2,3-d]pyrimidin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=N1 XKEBMWRWBWRQAO-UHFFFAOYSA-N 0.000 description 1
- AQXOFOIEABUGAI-UHFFFAOYSA-N 2,3,4a,5,6,7,8,8a-octahydro-1H-pyrido[4,3-d]pyrimidin-4-one Chemical compound C1CNCC2C(=O)NCNC21 AQXOFOIEABUGAI-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- NPRZWOJTSGFSBF-UHFFFAOYSA-N 2-chloropyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC(Cl)=C1 NPRZWOJTSGFSBF-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- GDIIPKWHAQGCJF-UHFFFAOYSA-N 4-Amino-2-nitrotoluene Chemical compound CC1=CC=C(N)C=C1[N+]([O-])=O GDIIPKWHAQGCJF-UHFFFAOYSA-N 0.000 description 1
- HJBCFHXEOPQFGF-UHFFFAOYSA-N 4-chloropyrido[2,3-d]pyrimidine Chemical compound C1=CC=C2C(Cl)=NC=NC2=N1 HJBCFHXEOPQFGF-UHFFFAOYSA-N 0.000 description 1
- MFUWUCHAQPUKDY-UHFFFAOYSA-N 4-chloropyrido[4,3-d]pyrimidine Chemical compound C1=NC=C2C(Cl)=NC=NC2=C1 MFUWUCHAQPUKDY-UHFFFAOYSA-N 0.000 description 1
- NZCRUBBNZGVREM-UHFFFAOYSA-N 4-chlorothieno[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CS2 NZCRUBBNZGVREM-UHFFFAOYSA-N 0.000 description 1
- TWTODSLDHCDLDR-UHFFFAOYSA-N 4-chlorothieno[3,2-d]pyrimidine Chemical compound ClC1=NC=NC2=C1SC=C2 TWTODSLDHCDLDR-UHFFFAOYSA-N 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-Lipoxygenase Proteins 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 101710011090 At3g55800 Proteins 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000020504 Collagenase family Human genes 0.000 description 1
- 108060005980 Collagenase family Proteins 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N Diacerein Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
- 102100010782 EGFR Human genes 0.000 description 1
- 101700039191 EGFR Proteins 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 101710031717 HNRNPK Proteins 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- 206010020583 Hypercalcaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N Isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- ZCSHNCUQKCANBX-UHFFFAOYSA-N Lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 1
- 108091007472 MAP kinase family Proteins 0.000 description 1
- 101710029807 MAPK14 Proteins 0.000 description 1
- 101710043851 MTR_3g055120 Proteins 0.000 description 1
- 102100015262 MYC Human genes 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003393 Mammary Paget's Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004331 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108090000823 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- SQCRPUKPEKTENK-UHFFFAOYSA-N N-(4-methyl-3-nitrophenyl)-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C([N+]([O-])=O)C(C)=CC=C1NC(=O)C1=CC=NC(N2CCOCC2)=C1 SQCRPUKPEKTENK-UHFFFAOYSA-N 0.000 description 1
- DKRNQKDMLWIACW-UHFFFAOYSA-N N-[4-methyl-3-(thieno[3,2-d]pyrimidin-4-ylamino)phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(NC=2C=3SC=CC=3N=CN=2)C(C)=CC=C1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 DKRNQKDMLWIACW-UHFFFAOYSA-N 0.000 description 1
- OVRGQJVRMLLGKM-UHFFFAOYSA-N N-[4-methyl-3-[(5-methylthieno[2,3-d]pyrimidin-4-yl)amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C=12C(C)=CSC2=NC=NC=1NC(C(=CC=1)C)=CC=1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 OVRGQJVRMLLGKM-UHFFFAOYSA-N 0.000 description 1
- WYYCRSZLFBSSGL-UHFFFAOYSA-N N-phenylpyrido[4,3-d]pyrimidin-4-amine Chemical class N=1C=NC2=CC=NC=C2C=1NC1=CC=CC=C1 WYYCRSZLFBSSGL-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 210000002997 Osteoclasts Anatomy 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 206010034636 Peripheral vascular disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 208000001685 Postmenopausal Osteoporosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940024999 Proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N Pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N Sodium orthovanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 229960005078 Sorbitan sesquioleate Drugs 0.000 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960004319 Trichloroacetic Acid Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N Trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000010019 Vascular System Injury Diseases 0.000 description 1
- 206010027701 Vascular injury Diseases 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000003286 arthritogenic Effects 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 230000003143 atherosclerotic Effects 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 230000003182 bronchodilatating Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 230000003011 chondroprotective Effects 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003413 degradative Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 229960004590 diacerein Drugs 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- MYIRARNXCGWFHI-UHFFFAOYSA-N ethoxyethane;2-methylpentane Chemical compound CCOCC.CCCC(C)C MYIRARNXCGWFHI-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 150000002309 glutamines Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 201000005569 gout Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002443 helper T lymphocyte Anatomy 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 201000002980 hyperparathyroidism Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000006542 morpholinylalkyl group Chemical group 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000002148 osteoclast Effects 0.000 description 1
- 201000000023 osteosclerosis Diseases 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OCFVSFVLVRNXFJ-UHFFFAOYSA-N potassium hydride Inorganic materials [H-].[K+] OCFVSFVLVRNXFJ-UHFFFAOYSA-N 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2R,3R,4S,5S,6R)-2-[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
This invention concerns a bicyclic compound of Formula (I), wherein:G is N, CH or C(CN);ring X is a 5- or 6-membered fused heteroaryl ring which contains 1, 2, or 3 heteroatoms selected from oxygen, sulphur and nitrogen;m is 0 - 2;R1 is a group such as hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl;each of R2 and R3 is hydrogen, halo, C1-6alkyl, C2-6alkenyl or C2-6alkynyl;R4 is a group such as hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, amino and N-C1-6alkylamino;R5 is a group such as hydrogen, halo, trifluoromethyl, cyano, nitro, amino and hydroxy, and q is 0 - 4;or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof;processes for its preparation, a pharmaceutical composition containing it and its use in the treatment of diseases or medical conditions mediated by cytokines.
Description
DERIVATIVES OF PYRIDINE AND PYRIMIDINE AND THEIR USE AS INHIBITORS
OF A MEDIATED DISEASE BY CYTOKIN
DESCRIPTION OF THE INVENTION This invention has to do with certain amide derivatives and their use as inhibitors of a cytokine-mediated disease. The invention also relates to the processes for the manufacture of novel amide derivatives, the pharmaceutical compositions containing them and their use in therapeutic methods, for example by virtue of the inhibition of a cytokine-mediated disease. The amide derivatives described in the present invention are inhibitors of the production of cytokines such as Tumor Necrosis Factor (hereinafter TNF), for example TNFa, and various members of the interleukin family (hereinafter IL), for example. IL-1, IL-6 and IL-8. Accordingly, the compounds of the invention will be useful in the treatment of diseases or medical conditions in which excessive cytokine production occurs, for example excessive production of TNFa or IL-1. It is known that cytokines are produced by a wide variety of cells such as monocytes and macrophages and that they give rise to a variety of physiological effects that are believed to be important in affective or medical conditions such as inflammation and immunoregulation. For example, TNFa and IL-1 have been implicated in the cell signaling cascade that is believed to contribute to the pathology of affective states such as inflammatory and allergic diseases and cytokine-induced toxicity. It is also known that, in some cellular systems, the production of TNFa precedes and mediates the production of other cytokines such as IL-1. Abnormal levels of cytokines have also been implicated in, for example, the production of physiologically active eicosanoids such as prostaglandins and leukotrienes, stimulation of the release of proteolytic enzymes such as collagenase, activation of the immune system, for example by stimulation of T helper cells, activation of osteoclast activity leading to calcium resorption, stimulation of proteoglycan release from, for example, cartilage, stimulation of cell proliferation and for angiogenesis. Cytokines are also believed to be involved in the production and development of affective states such as inflammatory and allergic diseases, for example inflammation of the joints (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastrointestinal tract (especially inflammatory bowel disease). , ulcerative colitis, Crohn's disease and gastritis), skin disease (especially psoriasis, eczema and dermatitis) and respiratory disease (especially asthma, bronchitis, allergic rhinitis, respiratory distress syndrome in adult and chronic obstructive pulmonary disease), and in the production and development of various cardiovascular and cerebrovascular disorders such as congestive heart disease, myocardial infarction, the formation of atherosclerotic plaques, hypertension, platelet aggregation, angina, stroke, Alzheimer's disease, reperfusion injury, vascular injury that includes tenosis and peripheral vascular disease, and for example, various disorders of bone metabolism such as osteoporosis (which includes senile and postmenopausal osteoporosis), Paget's disease, bone metastasis, hypercalcemia, hyperparathyroidism, osteosclerosis, osteoporosis and periodontitis, and abnormal changes in the bone metabolism that may accompany rheumatoid arthritis and osteoarthritis. Excessive cytokine production has also been implicated in the mediation of some complications of bacterial, fungal and / or viral infections such as endotoxic shock, septic shock and toxic shock syndrome and in the mediation of some complications of CNS surgery or injury. such as neurotrauma and ischemic attack. Excessive cytokine production has also been implicated in the mediation or exacerbation of the development of diseases involving cartilage or muscle resorption., pulmonary fibrosis, cirrhosis, renal fibrosis, cachexia found in some chronic diseases such as malignant disease and acquired immunodeficiency syndrome (AIDS), tumor invasion and tumor metastasis and multiple sclerosis. Evidence of the central role played by TNFa in the cellular signal cascade that gives rise to rheumatoid arthritis is provided by the efficiency in clinical studies of TNFα antibodies (The Lancet, 1994,
344, 1125 and British Journal of Rheuology, 1995, 34, 334). Thus, cytokines such as TNFa and IL-1 are believed to be important mediators of a considerable range of diseases and medical conditions. Accordingly, it is expected that the inhibition of the production of and / or effects of these cytokines will be of benefit in the prophylaxis, control or treatment of such diseases and medical conditions. Without wishing to imply that the compounds described in the present invention possess pharmacological activity only by virtue of an effect of an individual biological process, it is believed that the compounds inhibit the effects of cytokines by virtue of the inhibition of the enzyme p38 kinase. The p38 kinase, otherwise known as cytokine suppressor binding protein (hereafter CSBP) and reactivating kinase (hereafter RK), is a member of the family of mitogen-activated protein kinase enzymes (from here hereinafter MAP) which are known to be activated by physiological stress such as that induced by ionizing radiation, cytotoxic agents, and toxins, for example endotoxins such as bacterial lipopolysaccharides and by a variety of agents such as cytokines, for example TNFa and IL- 1. It is known that p38 kinase phosphorylates some intracellular proteins that are involved in the cascade of enzymatic steps that leads to the biosynthesis and excretion of cytokines such as TNFa and IL-1. Known inhibitors of p38 kinase have been reviewed by G J Hanson in Expert Opinions on Terapeutic Patents, 1997, 7, 729-733. The p38 kinase is known to exist in isoforms identified as p38a and p38β. The compounds described in the present invention are inhibitors of the production of cytokines such as TNF, in particular of TNFa, and various interleukins, in particular IL-1. It is described in J. Medicinal Chemistry, 1995, 38,
3780-3788, that some 4-anilinopyrido [4, 3-d] pyrimidines are inhibitors of epidermal growth factor receptor tyrosine kinase activity. One of the compounds described therein is 7-amino-4- (3-acetamidoanilino) -pyrido [4, 3-d] pyrimidine. Accordingly, the present invention provides a bicyclic compound of Formula (I):
wherein: G is N, CH or C (CN); Ring X is a 5 or 6 membered fused heteroaryl ring containing 1, 2 or 3 heteroatoms selected from oxygen, sulfur and nitrogen; m is 0, 1 or 2; R1 is hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulfamoyl, C6-6 alkyl, C2-6 alkenyl, C2_6 alkynyl, C6_6 alkoxy, -O- ( C? -3) -O-alkyl of C? -6S (O) p- (where n is 0-2), N-alkylamino of C? -6, N, N- (Ci-e alkyl) ) 2-amino, Ci-e alkoxycarbonyl, N-alkylcarbamoyl of C? -6,? T,? T- (Ci-β) alkylcarbamoyl, C2_6 alkanoyl, C? _6 alkanoyloxy, C? -6 alkanoylamino, N-alkylsulfamoyl of C? -6, N, N- (C? _6 alkyl) 2-sulfamollo, C? -6 alkylsulfonylamino, C? - alkylsulfonyl- &N- (Ci-b) alkyl amino, or R1 is of the Formula (IA): A- (CH2) PB- (IA) wherein A is halo, hydroxy, Ci-e alkoxy, C? -6 S (0) n- alkyl (where n is 0 -2), cyano, amino, N-alkylamino of C? -6, N, N- (C? -6-alkyl) 2-amino, carboxy, C? _6-alkoxycarbonyl, carbamoyl, N-alkylcarbamoyl of C? -6 or N, N- (C? _s) 2-carbamoyl alkyl, p is 1-6, and B is a bond, oxy, imino,
N- (C? _6 alkyl) imino or -C (0)? H-, with the proviso that p is two or more unless B is a bond or -C (0)? H-, or R1 is of the Formula (IB): D-E- (IB) wherein D is aryl, heteroaryl or heterocyclyl and E is a bond, C6-6 alkylene, C6-6 alkyleneoxy, oxy, imino,? T- (alkyl) Ci-e) imino, C? -6 alkyleneimino, N- (C? -6) alkyl- C? -6-alkylene imino, C? -6 alkylene-C? -6 alkylene, C-alkylene imino? -6-Ci-e-alkylene, 7- (Ci-e-alkyl) -alkyleneimino-C-6-alkylene of C? -6, -C (0)? H-, -S02? H-, - ? HS02- or C2_6 alkanoylimino, and any aryl, heteroaryl or heterocyclyl group in a R1 group may be optionally substituted with one or more groups selected from hydroxy, halo, C6-6alkyl, C6-6alkoxy, carboxy, C6-6alkoxycarbonyl. , carbamoyl, N-alkylcarbamoyl of C? _6, N- (Ci-β) alkylcarbamoyl, C2-6 alkanoyl, amino, N-alkylamino of C? _6 and N, T- (C? -6 alkyl) 2-amino, and any heterocyclyl group in a R1 group can be optionally substituted with one or two oxo or thioxo substituents, and any of the R1 groups defined above comprising a CH2 group that is bonded to two carbon atoms or to a CH3 group that is attached to a carbon atom may optionally carry in each of the groups CH2 or CH3 a substituent selected from hydroxy, amino, C6-6 alkoxy, N-alkylamino of C6-6, N, N- ( C? _6) 2-amino and heterocyclyl; R2 is hydrogen, halo, C? _6 alkyl, alkenyl of
C2_6 or C2-6 alkynyl / R3 is hydrogen, halo, C6_6 alkyl, C2_6 alkenyl or C2_6 alkynyl; R 4 is hydrogen, hydroxy, C?-6 alkyl, C?-6 alkoxy, amino, C?-6-N-alkylamino, N, N- (C?-6-alkyl) 2-amino, C 2-6 hydroxyalkoxy , C6-6 alkoxy, C2_6 alkoxy, C2-6 aminoalkoxy, C6-6 alkylamino, C2-6 alkoxy, N, N- (C6-6alkyl) 2-aminoalkoxy of C6-6 or C3_7 cycloalkyl, or R4 is of Formula (IC): -K-J (IC) wherein J is aryl, heteroaryl or heterocyclyl and
K is a bond, oxy, imino, N- (Ci-β) -imino alkyl, C?-6-oxyalkylene, C?-6-iminoalkylene, N- (C?-6-alkyl) -iminoalkylene of C?-6, -? HC (O) -, -S02? H-, -? HS02- or -NHC (O) -alkylene of C? -6-, and any aryl, heteroaryl or heterocyclyl group in a group R4 can be optionally substituted by one or more groups selected from hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulfamoyl, C? -6 alkyl, C2-6 alkenyl, C? _6 alkynyl, C? _6, -0- (C? -3 alkyl) -0-, Ci-S (0) alkyl n- (where n is 0-2), N-alkylamino of C? -6, N, N- (C? -6) 2amino alkyl, C? _6 alkoxycarbonyl, C? -6 N-alkylcarbamoyl,? T, N- (Ci-e) alkylcarbamoyl, C? -6 alkanoyl, alkanoyloxy C? -6, C? -6 alkanoylamino,? -C6 alkylsulfamoyl,? 7,? 7, (C? _6 alkyl) 2-sulphamoyl, C? -6 alkylsulfonylamino, and Ci-.beta.-N-alkylsulfonyl - (C? _6) amino alkyl, or any aryl, heteroaryl or heterocyclyl in a group R4 can be optionally substituted with one or more groups of the Formula (IA '): (IA') wherein A1 is halo, hydroxy, C? -6 alkoxy, cyano, amino, N-alkylamino of C? _6, N, N- (C6_6 alkyl) 2-amino, carboxy, C6_6 alkoxycarbonyl, carbamoyl, C6_6-N-alkylcarbamoyl or N, N- (Ci_d) 2carbamoyl alkyl, p is 1-6, and B1 is a bond, oxy, imino, N- (alkyl of
C? _6) imino or -? HC (0) -, with the proviso that p is 2 or more unless B1 is a bond or -? HC (0) -, or any aryl, heteroaryl or heterocyclyl group in a R4 group can be optionally substituted with one or more groups of the Formula
(IB '): E ^ D1 (IB') wherein D1 is aryl, heteroaryl or heterocyclyl and
E1 is a bond, C? _6 alkylene, C? -6 oxyalkylene, oxy, imino, N- (C? _6) imino alkyl, C? _6 iminoalkylene, N- (Ci-e alkyl) -iminoalkylene of C? -6, C? _6-oxyalkylene alkylene of C? -6, C? -6-ip? inoalkylene alkylene of Ci-e, alkylene of C? -6-N- (C? -6 alkyl) ) -iminoalkylene of Cj-6, -NHC (O) -, -NHS02-, -S02NH- or -NHC (O) -alkylene of C? _6-, and any aryl, heteroaryl or heterocyclyl group in a substituent on R4 can optionally substituted with one or more groups selected from hydroxy, halo, C? -6 alkyl, C? _6 alkoxy, carboxy, C? _6 alkoxycarbonyl, carbamoyl, C? -6 N-alkylcarbamoyl, N- ( e) 2-carbamoyl, C2-6 alkanoyl, amino, N-alkylamino of C6-6 and N, N- (C6-6 alkyl) 2-amino, and any cycloalkyl group of C3-7 or heterocyclyl in a group R4 may be optionally substituted with one or two oxo or thioxo substituents, and any of the R4 groups defined above that comprise a CH2 group which is attached to two carbon atoms or a CH3 group that binds to a carbon atom can optionally carry over each CH2 or CH3 group a substituent selected from hydroxy, amino, C6-6 alkoxy, N-alkylamino of C? -6, N, N- (C? -6-alkyl) 2-amino and heterocyclyl; R5 is hydrogen, halo, trifluoromethyl, cyano, nitro, amino, hydroxy, C? -6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C? -6 alkoxy, C? -6 N-alkylamino or N, N- (C? _6) 2amino alkyl; q is O, 1, 2, 3 or 4; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof; with the proviso that 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine is excluded. It is to be understood that the bicyclic ring within the compound of Formula (I) is shown with a hydrogen atom attached to the carbon between the α-atom. and group G to indicate that this position is not replaced. Accordingly, it will be understood that this hydrogen atom can not be replaced by a substituent R1. It should also be understood, however, that when G is a CH group, that CH group can carry any of the substituents R1. It should be understood that, with respect to some of the compounds of Formula (I) defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any racemic or optically active form which possesses the property of inhibiting cytokines, in particular TNF. Syntheses of the optically active forms can be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis of optically active starting materials or by resolution of a racemic form. Likewise, the inhibitory properties against TNF can be evaluated using the standard laboratory techniques referred to hereinafter. To avoid doubt, it should be understood that when, for example, R "1" is a group of Formula (IB): D-E- (IB) and the linking group E is, for example, an alkyleneoxy group of C ? _6 such as -CH2CH20-, is a CH2 group that binds to D and the O atom that binds to the bicyclic ring within Formula (I). Likewise when, for example, R4 is a group of Formula (IB '): -E ^ D1 (IB') and the linking group E1 is, for example, an iminoalkylene group of C? _6 such as -NHCH2CH2-, is a CH2 group that binds to D1 and the NH group that binds to the bicyclic ring within Formula (I). A similar convention applies to other bidentate linking groups.
In this specification the term "alkyl" includes straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific to the straight chain version only. For example, "CiV alkyl includes propyl, isopropyl, and t-butyl." However, references to individual alkyl groups such as "propyl" are specific to the straight chain version only and references to the alkyl chain groups individual branched such as 'isopropyl' are specific for the branched chain version only.An equal convention applies to other radicals, for example "C2-6 aminoalkoxy" includes 2-aminoethoxy, 2-aminopropoxy and 3-amino-2- Methylpropoxy The term "halo" refers to fluoro, chloro, bromo and I. The term "aryl" refers to phenyl or naphthyl When a group R4 involves a group D1 and D1 is aryl, that "aryl" refers to to phenyl, indenyl, indanyl, naphthyl, tetrahydronaphthyl or fluorenyl The term "heteroaryl" refers to, unless otherwise specified, a monocyclic, bicyclic or tricyclic ring of 5 to 14 members which is unsaturated or partially unsaturated, with one to five heteroatoms in the ring selected from nitrogen, oxygen and sulfur, wherein a -CH2- group can be optionally replaced by a -C (0) -, a nitrogen atom in the ring can optionally carry an alkyl group of C? _6 or a nitrogen atom in the ring and / or sulfur in the ring may optionally be oxidized to form N-oxide and / or the S-oxides. Examples of "heteroaryl" include thienyl, furyl, pyranyl, pyrrolyl, pyrazolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, thiazolyl, oxazolyl, isoxazolyl, pyridyl, pyridyl-N-oxide, oxopyridyl, oxoquinolyl, pyrimidinyl, pyrazinyl, oxopyrazinyl, pyridazinyl, indolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, quinolyl, N-methyloxoquinolyl, isoquinolinyl, quinazolinyl, xanthenyl, quinoxalinyl, indazolyl, benzofuranyl, cinolinolyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl, S, S-dioxodibenzothiophenyl, dibenzo-1,4-dioxinyl, phenoxythinyl, phenoxazinyl, dibenzothiinyl, phenothiazinyl, thiantrenyl, benzofuropyridyl, pyridoindolyl, acridinyl and phenanthridinyl. When a group R4 involves a group D1 and D1 is heteroaryl, this "heteroaryl" preferably refers to furyl, thienyl, pyrrolyl, pyrrolinyl, oxazolyl, isoxazolyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl. , pyrazinyl, benzofuranyl, indolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl or xanthenyl, or benzo derivatives such as 2, 3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, indolinyl, isoindolinyl, chromanyl and isochromanyl, more preferably that "heteroaryl" refers to furyl, thienyl, 3-pyrrolinyl, isoxazolyl, thiazolyl, pyridyl, benzothienyl, benzofurazanyl, quinolyl, carbazolyl, dibenzofuranyl or dibenzothiophenyl. Ring X is a 5 or 6 membered fused heteroaryl ring containing 1, 2 or 3 heteroatoms selected from oxygen, sulfur and nitrogen. Suitably, the X ring is unsaturated or partially unsaturated wherein a -CH2- group can optionally be replaced by a -C (O) - a nitrogen atom in the ring can optionally carry a C? -6 alkyl group or an atom of nitrogen in the ring and / or sulfur in the ring can optionally be oxidized to form N-oxide and / or the S-oxides. Examples of suitable fused heteroaryl ring di-radicals include tiendiyl, furandiyl, imidazoldiyl, pyrazoldiyl, oxazoldiyl, isoxazoldiyl, thiazoldiyl, isothiazoldiyl, 1,2, 3-oxadiazoldiyl, 1,2,3-triazoldiyl, pyridindiyl, pyrimidindiyl, pyrazindiyl., pyridazindiyl and 1, 3, 4-triazindiyl. Examples of the mono-radical of suitable bicyclic rings formed by the fusion of the X-ring into the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) include furopyridyl, furopyrimidinyl, thienopyridyl, thienopyrimidinyl, pyrrolpyridyl, pyrrolpyrimidinyl, pyrrolinopyridyl , pirrolinopirimidinilo, oxopirrolino-pyridyl, oxopirrolinopirimidinilo, oxazolpiridilo, oxazolopyrimidinyl, oxazolinopiridilo, oxazolinopirimidinilo, oxooxazolinopiridilo, oxooxazolinopirimidinilo, isoxazol-pyridyl, isoxazolpirimidinilo, tiazolpiridilo, thiazolopyrimidinyl, tiazolinopiridilo, tiazolinopirimidinilo, oxotiazolinopiridilo, oxotiazolinopirimidinilo, isothiazol-pyridyl, isotiazolpirimidinilo, imidazolpiridilo, oxoimidazolinopiridilo imidazolinopiridilo, purinyl, imidazolinopyrimidinyl, oxoimidazolinopyrimidinyl, pyrazol-pyridyl, pyrazolpyrimidinyl, pyrazolopyridyl, pyrazolopyrimidinyl, oxopyrazolinopyridyl, oxopyrazolino-pyrimidinyl, ftiridinyl, pyridopyrimidinyl, pyrimido-pyrimidinyl and pteridinyl. The term "heterocyclyl" refers to, unless otherwise specified, a 3-14 membered mono or bicyclic ring, which is fully saturated, with up to five ring heteroatoms selected from nitrogen, oxygen and sulfur wherein a -CH2- group can optionally be replaced by a -C (0) - or a nitrogen atom in the ring can optionally carry an alkyl group of Ci-e. Examples of such heterocyclyls include morpholinyl, 7-methylmorpholinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, N-methylpiperidinyl, piperazinyl and quinuclidinyl. When a group R4 involves a group D1 and D1 is heterocyclyl, this "heterocyclyl" preferably refers to oxiranyl, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1,1-dioxidoisothiazolidinyl, morpholinyl, tetrahydro-1, - thiazinyl, 1,1-dioxotetrahydro-l, 4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl, preferably for, azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, 1, l-dioxidoisothiazolidin-2 -yl, morpholino, 1, l-dioxotetrahydro-4H-l, 4-thiazin-4-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-1-yl, piperidino, piperazin-1-yl or homopiperazin -1-ilo. A suitable value for such a group having 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperi-dinyl, 2,5-dioxopyrrolidinyl, , 5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Where optional substituents are selected from "one or more" groups it can be understood that this definition includes all substituents being selected from one of the specified groups or substituents being selected from two or more of the specified groups. Conveniently there may be 1, 2 or 3 of such optional substituents. For example, where optional substituents are selected from one or more groups selected from halo, C? -6 alkoxy and C? -6 alkyl, examples of possible combinations of substituents include 1) a bromo group, 2) two chlorine groups, 3) a methoxy, ethoxy and propoxy substituent, 4) a fluoro and a methoxy group, 5) a methoxy group, a methyl group and an ethyl group, and 6) a chloro, a methoxy and an ethyl group. Examples of C? -4 alkyl include methyl, ethyl and isopropyl. Examples of C?-6 alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of C? -Salkoxy include C? -4 alkoxy and C2-4 alkoxy and include methoxy, ethoxy, propoxy and t-butoxy. Examples of C? -6 alkanoylamino include formamido, acetamido and propionylamino. Examples of C? -6S (0) n alkyl, wherein n is 0-2 and include methylthio, ethylthio, methylisulfinyl, ethylsulfinyl, methylsulfonyl and ethylsulfonyl. Examples of C2-6 alkanoyl include propionyl and acetyl. Examples of N-alkylamino of C? -6 include N-methylamino and N-ethylamino. Examples of N, N- (C6_6 alkyl) 2-amino include N, N-dimethylamino, N, N-diethylamino and N-ethyl-N-methylamino.
Examples of C6-6 alkoxy C2-6 alkoxy include methoxyethoxy and propoxybutoxy. Examples of N- (C6-alkyl) aminoalkoxy of C2-6 include 3- (N-methylamino) propoxy and 4- (α-ethylamino) butoxy.
Examples of N, N- (C? -6-alkyl) 2-aminoalkoxy of C2-e include 2- (N, N-dimethylamino) ethoxy and 3- (N-methyl-N-ethylamino) propoxy. Examples of C3-7 cycloalkyl include cyclopropyl and cyclohexyl. Examples of C2_6 alkenyl include vinyl, allyl and 1-propenyl. Examples of C2-6 alkynyl include ethynyl, 1-propynyl and 2-propynyl. Examples of C2-6 hydroxyalkoxy include 2-hydroxyethoxy and 2-hydroxyproxy. Examples of C 1-6 alkylsulfonylamino include methanesulfonamido and ethanesulfonamido. Examples of C ?6-N- (C? -6) alkyl amino alkylsulfonyl include N-ethylmetanesulfonamido and N-butylethanesulfonamido. Examples of N- (C6-alkyl) sulfamoyl include N-methylsulfamoyl and N-ethylsulphamoyl. Examples of N, N- (C6_6 alkyl) 2-sulfamoyl include N, N-dimethylsulphamoyl and N-methyl-N-ethylsulphamoyl. Examples of N- (Ci-e alkyl) carbamoyl include N-methylcarbamoyl and N-ethylcarbamoyl. Examples of N, N- (C6_6) alkylcarbamoyl include N, N-dimethylcarbamoyl and N-methyl-N-ethylcarbamoyl. Examples of C 1-6 alkanoyloxy include propionyloxy, acetyloxy and formyloxy. Examples of -O-C ?3-0-alkyl include -toxyethoxy- and -oximetoxy- (ie, a bidentate substituent, attached to the ring at two adjacent positions). In linking groups B, E, B ±, E1 and K that fall within the definition of R1 and R4, examples of generic terms include the following. Examples of C? _6 alkylene include -CH2CH2- and -CH2CH (CH3) CH2-. Examples of C 1-6 alkyleneoxy include -CH 2 CH 20- and -CH 2 CH (CH 3) CH 20-. Examples of N- (Ci-β) -imino alkyl include -N (Me) - and -N ^ Pr) -. Examples of alkyleneimino of C? _s include -CH2CH2NH- and -CH2CH (CH3) CH2NH-. Examples of N- (Ci-β alkyl) -alkyleneimino of C? -6 include -CH2CH2? (Me) - and -CH2CH (CH3) CH2? ^ Pr) -. Examples of C2-6 alkanoylimino include -CH2CH2C (0)? H- and -CH2CH (CH3) CH2C (0)? H-. Examples of C? -6 oxyalkylene include -OCH2CH2- and -OCH2CH (CH3) CH2-. Examples of C? -6 iminoalkylene include -? HCH2CH2- and -? HCH2CH (CH3) CH2-. Examples of N- (C? _6 alkyl) iminoalkylene of C? -6 include -? (Me) CH2CH2- and -? (IPr) CH2CH (CH3) CH2-. Examples of -? HC (O) alkylene of C? -6- include -? HC (0) CH2CH2- and -? HC (0) CH2CH (CH3) CH2-. When, as defined above, any of the R1 or R4 groups defined above that comprise a CH2 group that is bonded to 2 carbon atoms or a CH3 group that is attached to a carbon atom may optionally carry in each of the groups CH2 or CH3 of a substituent selected from hydroxy, amino, C? -6 alkoxy, C? -6-N, C, -6-, N- (C? -6 alkyl) 2-amino and heterocyclyl, suitable substituents thus formed include, for example, substituted C? -6 heterocyclylalkoxy groups such as 2-hydroxy-3-piperidinopropoxy and 2-hydroxy-3-morpholinopropoxy, substituted C? -6 aminoalkoxy groups such as 3-amino-2-hydroxypropoxy groups N-alkylaminoalkoxy substituted C? -6-alkoxy C6-6 alkoxy such as 2-hydroxy-3-methylaminopropoxy, substituted N, N- (C1-β alkyl) 2-aminoalkoxy groups of C? -6 such as 3-dimethylamino- 2-hydroxypropoxy, 3- [N- (3-dimethylaminopropyl) -N-methylamino] propoxy and 3- [N- (3-dimethylaminopropyl) -N-methylamino] - 2-hydroxypropoxy, substituted C? -6 heterocyclylalkylamino groups such as 2-hydroxy-3-piperidinopropylamino and 2-hydroxy-3-morpholinopropylamino, substituted C? -6 aminoalkylamino groups such as 3-amino-2-hydroxypropylamino, N groups -alkylamino of C? -6 substituted C? -6-alkylamino such as 2-hydroxy-3-methylaminopropylamino, substituted N, N- (C? -6 alkyl) 2-aminoalkylamino groups, such as 3-dimethylamino- 2-hydroxypropylamino, 3- [N- (3-dimethylamino-propyl) -N-methylamino] propylamino and 3- [N- (3-dimethylamino-propyl) -N-methylamino] -2-hydroxypropylamino, C N-6-substituted N-alkylamino groups of C ?_6 alkyl substituted such as 2-dimethylaminoethylaminomethyl, 3-dimethylaminopropylaminomethyl, 3-dimethylamino-2,2-dimethylpropylaminomethyl, 2-morpholinoethyl-aminomethyl, 2-piperazin-1-ylethylaminomethyl and 3-morpholino-propylaminomethyl. Preferably the values of R1, R2, R3, R4, R5, G, X, q and m are as follows. Preferably G is? or C (C?), more preferably G is? A preferred example of the di-radical of a fused heteroaryl ring suitable for the X-ring is thianediyl, furandiyl, imidazoldiyl, pyrazoldiyl, oxazoldiyl, thiazoldiyl, pyridindiyl, pyrimidindiyl or pyrazindiyl. A more preferred example of the di-radical of a fused heteroaryl ring suitable for the X-ring is thianediyl, thiazoldiyl, pyridindiyl or pyrazindiyl. A preferred example of the mono-radical of a suitable bicyclic ring formed by the fusion of the X ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolpyrimidinyl, pyrrolinopyrimidinyl, oxopyrrolinopyrimidinyl, oxazolpyrimidinyl , oxazolinopirimidinilo, oxooxazolinopirimidinilo, isoxazol-pyrimidinyl, thiazolopyrimidinyl, tiazolinopirimidinilo, oxotiazolinopirimidinilo, isotiazolpirimidinilo, purinyl, imidazolinopirimidinilo, oxoimidazolinopirimidinilo pyrazol-pyrimidinyl, pirazolinopirimidinilo, oxopirazolino-pyrimidinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl. A more preferred example of the mono-radical of a suitable bicyclic ring formed by the fusion of the X-ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolpyrimidinyl, oxazolpyrimidinyl, thiazolopyrimidinyl, purinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl. A further, more preferred example of the mono-radical of a suitable bicyclic ring formed by the fusion of the X-ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is furo [3,2-d] pyrimidinyl, furo [2,3-d] pyrimidinyl, thieno [3,2-d] pyrimidinyl, thieno [2,3-d] pyrimidinyl, pyrrol [3,2-d] pyrimidinyl, pyrrol [2,3-d] pyrimidinyl, oxazole [5,4-d] pyrimidinyl, oxazol [4, 5-d] pyrimidinyl, thiazole [5,4-d] pyrimidinyl, thiazol [4, 5-d] pyrimidinyl, purinyl, pyrido [2, 3-d] pyrimidinyl , pyrido [3,4-d] pyrimidinyl, pyrido [4, 3-d] pyrimidinyl, pyrido [3,2-d] pyrimidinyl, pyrimido [4,5-d] pyrimidinyl, pyrimido [5,6- d] pyrimidinyl or pteridinyl. A particular preferred example of the mono-radical of a suitable bicyclic ring formed by the fusion of the X-ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is 6-oxopyrrolino [2,3-d] pyrimidine- 4-yl, 6-oxopyrrolino [3,2-d] pyrimidin-4-yl, 2-oxooxazolino [5, 4-d] pyrimidin-7-yl, 2-oxothiazolino [5, 4-d] pyrimidin-7- ilo, 2-oxooxazolino [4, 5-d] pyrimidin-7-yl, 2-oxothiazolino [4, 5-d] pyrimidin-7-yl, 2-oxoimidazolino [4, 5-d] pyrimidin-7-yl, 3-oxopyrazolino [3,4-d] pyrimidin-4-yl or 3-oxopyrazolino [4, 3-d] pyrimidin-7-yl. Another more preferred example of the mono-radical of a suitable bicyclic ring formed by the fusion of the X ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is thieno [3,2-d] pyrimidinyl, thieno [ 2,3-d] pyrimidinyl, thiazole [5,4-d] pyrimidinyl, pyrido [2, 3-d] pyrimidinyl, pyrido [3,4-d] pyrimidinyl, pyrido [4, 3-d] irimidinyl, pyrido [ 3,2-d] pyrimidinyl or pteridinyl. Particularly, a more preferred example of the mono-radical of a suitable bicyclic ring formed by the fusion of the X-ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is thieno [3,2-d] pyrimidine- 4-yl, thieno [2,3-d] pyrimidin-4-yl, thiazol [5,4-d] pyrimidin-7-yl, pyrido [2, 3-d] pyrimidin-4-yl, pyrido [3, 4-d] pyrimidin-4-yl, pyrido [4, 3-d] pyrimidin-4-yl, pyrido [3,2-d] pyrimidin-4-yl or pteridin-4-yl. Preferably m is 0 or m is 1 or 2 and each R "1" is independently hydroxy, halo, C? -6 alkyl, C? -6 alkoxy, C? -6S alkyl (0) n- (where n is 0-2), N, N- (C? -6 alkyl) 2-aminoalkyl of C? -6, N, N- (Ci-e alkyl) 2-carbamoylalkoxy of C? -6, N, N- (C? _6 alkyl) 2? Aminoalkoxy of C? -6, C? -6S alkyl ( 0) 2-alkoxy, N, N- (Ci-e alkyl) 2 amino-N- (Ci-e alkyl) C 1-6 alkylamino, N, N- (C 6 alkyl) 2 amino alkylaminoalkyl of C ? -6, C? -6 heterocyclylalkyl, C? -6 heterocyclylkoxy, heterocyclyloxy, C? -6-C6-C6-heterocyclylalkylamino, or C? _6 heteroaryl-C1-C6-alkyl. Most preferably m is 0 or m is 1 and each R1 is independently hydroxy, halo, C6-6 alkyl, C6-6 alkoxy, C6-6S (0) n- alkyl (where n is 0- 2), N, N- (C? -6 alkyl) 2-aminoalkyl of C? -6, N, N- (Ci-d alkyl) 2-carbamoylalkoxy of C? -6, N, N- (C? _6 alkyl) ) C 2 -6-aminoalkoxy, C ?6S (0) 2-C alco-6 alkoxy, N, N- (Ci-β) alkyl 2-amino- N- (C?-6 alkyl) alkylamino C? _6, N, N- (Ci-e alkyl) 2-aminoalkylamino of C? -6-C? -6 alkyl, piperidin-1-ylalkyl of C? -6, homopiperidin-1-ylalkyl of C? -6 , N- (C? -6 alkyl) piperidin-1-ylalkyl of C? -6, N- (
Ci-β) homopiperidin-1-ylalkyl of C? -6, piperazin-1-ylalkyl of C? -6, 4-alkylpiperazine of C? -6-l-ylalkyl of C? -6, homopiperazinyl-1-ylalkyl of C? _6, 4-alkyl-homopiperazinyl of C? -6-l-ylalkyl of C? -6, pyrrolidinylalkoxy of C? -6, piperidinylalkoxy of C? -6, homopiperidinylalkoxy of C? -6, N- (C? -6) pyrrolidinylalkoxy of C? -6, N- (alkyl of
Ci-β) piperidinylalkoxy of C? -6, N- (alkyl of
Ci-ß) homopiperidinylalkoxy of C? -6, morpholinylalkoxy of C? -6, piperazinylalkoxy of Ci-β, N- (C? -6 alkyl) piperazinylalkoxy of C? -6, homopiperazinylalkoxy of C? -6, N- (Ci-d alkyl) C? -6 homopiperazinylalkoxy, pyrrolidinyloxy, N- (C? _6 alkyl) pyrrolidinyloxy, piperidinyloxy, N- (Ci-β alkyl) piperidinyloxy, homopiperidinyloxy, N- (C? 6) Homopiperidinyloxy, C? -6-C6-C6-alkyl, C6-6 thiazolylalkoxy or C6-6 pyridylalkoxy. Further more preferably m is 0 or m is 1 and each R1 is independently hydroxy, halo, C6-6 alkyl, C6e alkoxy, Ci-eS alkyl (0) n- (where n is 0-2) , N, N- (C? -6 alkyl) 2-aminoalkyl of C? -6, N, N- (C? -6 alkyl) 2-carbamoyloalkoxy of C? -6, N, N- (C? -6 alkyl) ) C 2 -6-aminoalkoxy, C?-C6-alkyl (0) 2-C alco-6-alkoxy, N, N- (C?-6-alkyl) 2-amino- N- (C?-6-alkyl) C? _6 alkylamino, N, N- (Ci-e alkyl) 2-aminoalkylamino of C? -6-C? -6 alkyl, piperazin-1-ylalkyl of C? -6, 4-alkylpiperazine of C? -6 -l-ilalkyl
C? -6, homopiperazinyl-1-ylalkyl of C? -6, 4-alkylhomopiperazinyl of C? -6-l-ylalkyl of C? -6, pyrrolidinylalkoxy of C? _6, pipendylalkyloxy of C? -6, N- ( C? -6 alkyl) pyrrolidinylalkoxy of C? -6, N- (C? _6 alkyl) piperidinylalkoxy of C? -6, morpholinylalkoxy of C? _6, piperazinylalkoxy of C? -6, N- (C? -6) C? -6 piperazinylalkoxy, C? -6 homopiperazinylalkoxy, N- (C? _6 alkyl) C? -6 homopiperazinylalkoxy, pyrrolidinyloxy, piperidinyloxy, C? -6-C? pyridylalkoxy of C? _6. More particularly m is 0 or om is 1 and each R1 is independently methyl, methoxy, methylthio, methylisulfinyl, methylsulfonyl, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 2-diisopropylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy , 2-piperidinoethoxy, N-methylpiperidin-2-ylmethoxy, N-methylpiperidin-3-ylmethoxy, 2-pyrrolidin-1-ylethoxy, 2- (N-methylpyrrolidin-2-yl) ethoxy, N-methyl-5-oxopyrrolidin- 2-ylmethoxy, 3-pyrrolidin-1-ylpropoxy, 2- (2-oxoimidazolidin-1-yl) ethoxy, 2- (4-methylpiperazin-1-yl) ethoxy or 3-pyrid-3-ylpropoxy. In addition, more particularly m is 0 or m is 1 and each Rx is independently methyl, methoxy, methylthio, 2-diisopropylaminoethoxy, 3-diethylaminopropoxy, 3-morpholinopropoxy or 3-pyrrolidin-1-ylpropoxy. Even more particularly m is 0 or m is 1 and each R1 is independently methyl or methylthio. Preferably R2 is hydrogen, C? _6 alkyl or halo. Most preferably R2 is hydrogen, alkyl of
C? - or halo. Particularly R2 is hydrogen, methyl, fluoro or chloro, more particularly methyl. Preferably R3 is hydrogen, C? -6 alkyl or halo. Most preferably R3 is hydrogen, alkyl of
C? -4 or halo. Particularly R3 is hydrogen, methyl, fluoro or chloro, more particularly hydrogen. Preferably q is 0 or 1, more preferably q is 0. Preferably R4 is aryl or heteroaryl optionally substituted by one or more groups selected from halo, cyano, C? -6 alkyl, C? _6 alkoxy, N, N- (C? -6) 2-amino or heterocyclyl alkyl. More preferably R4 is aryl or heteroaryl optionally substituted by one or more groups selected from halo, cyano, C6_6alkyl, C6_6alkoxy, N, N- (C6_6 alkyl) 2amino, pyrrolidine -1-yl, piperidinyl, morpholino, piperazinyl, 4-alkyl-piperazine of C6- l-yl, homopiperazinyl-1-yl or 4-alkyl-homopiperazinyl of C6-6-1-yl. In addition, R 4 is preferably phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by one or two halo, trifluoromethyl, cyano, C 1-4 alkyl, C 1-4 alkoxy, -0- (C 1-3 alkyl) -O-, N, N- (C? -4) 2-amino alkyl, C 1-6 alkanoylamino , C 1 -C 6 alkylsulfonyl (Cys alkyl) amino, phenyl (optionally substituted by one or two halo groups), furyl, azetidinyl, pyrrolidinyl, 3-pyrrolinyl, piperidino, homopiperidinyl, morpholino, piperazinyl, homopiperazinyl, N - (C? -6 alkyl) piperazinyl and N- (C? -6 alkyl) homopiperazinyl, or R4 is fluorenyl or dibenzofuranyl. Additionally most preferred R 4 is phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by one or two of halo, cyano, C? _4alkyl, C-4-4 alco alkoxy, N, N- (C alquilo-alkyl) -4) 2-amino, piperidinyl, morpholino or piperazinyl. Particularly R 4 is phenyl, furyl, isoxazolyl or pyridyl optionally substituted by one or more groups selected from fluoro, chloro, cyano, methyl, methoxy, N, N-dimethylamino or morpholino. Particularly in additional form R4 is phenyl, furyl, thienyl or pyridyl optionally substituted by one or two groups selected from fluoro, chloro, trifluoromethyl, cyano, methyl, methoxy, ethoxy, methylenedioxy, N, N-dimethylamino, acetamido, N- methylmetanesulfonamido, phenyl, 4-fluorophenyl, 4-chlorophenyl, furyl, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4-methylpiperazin-1-yl and 4-methylhomopiperazin-1-yl. Particularly in additional form R4 is phenyl optionally substituted by one or two groups selected from fluoro, chloro, trifluoromethyl, cyano, methyl, methoxy, ethoxy, methylenedioxy, N, N-dimethylamino, acetamido, N-methylmethanesulfonamido, phenyl, 4- fluorophenyl, 4-chlorophenyl, 2-furyl, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1 ilo, 4-methylpiperazin-1-yl and 4-methylhomopiperazin-1-yl. Particularly additionally R 4 is 1-fluorenyl or dibenzofuran-4-yl. More particularly R 4 is phenyl, 2-methylphenyl, 3- (N, N-dimethylamino) phenyl, 3-fluorophenyl, 3-methoxyphenyl, 4-cyanophenyl, 3,4-dimethoxyphenyl, 3-morpholinophenyl, 2-furyl, 2-chloropyrid -5-yl, 2-morpholinopyrid-4-yl or isoxazol-5-yl. In a more particular way R4 is phenyl, 3-fluorophenyl, 4-cyanophenyl, 2-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-ethoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 3- (N, N-dimethylamino) phenyl, 3-acetamidophenyl, 3- (4-fluorophenyl) phenyl, 3- (2-furyl) phenyl, 3-pyrrolidin-1-ylphenyl, 3-morpholinophenyl, 3-fluoro-5-pyrrolidin-1- ilphenyl, 3-fluoro-5-piperidinophenyl, 3-fluoro-5-morpholinophenyl or 3-morpholino-5-trifluoromethylphenyl. In a more particular way R4 is pyridyl optionally substituted by a group N, N-dimethylamino, N, N-diethylamino, pyrrolidin-1-yl, piperidino or morpholino. In a more particular way R4 is pyridyl optionally substituted by an N, N-dimethylamino, N, N-diethylamino, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, piperidino, homopipendin-1- ilo, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4-methylpiperazin-1-yl or 4-methylhomopiperazin-1-yl.
Even more particularly R 4 is 2-morpholinopyrid-4-yl. Preferably R.sup.4 is hydrogen or C? -6 alkoxy, more preferably C? -4 alkoxy, particularly hydrogen or methoxy. Preferably R5 is hydrogen. According to a preferred aspect of the invention, there is provided a compound of the Formula (I) wherein: the bicyclic ring formed by the fusion of the X-ring to the 6-membered heteroaryl ring containing adjacent nitrogen within the Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolpyrimidinyl, oxazolpyrimidinyl, thiazolopyrimidinyl, purinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl; m is O or m is 1 and each R 1 is independently hydroxy, halo, C 6 alkyl, C 6 alkoxy, alkyl
C? -6S (0) n- (where n is 0-2), N, N- (C?
6) 2-aminoalkyl of C? -6, N, N- (Ci-e alkyl) 2-carbamoylalkoxy of C? -6, N, N- (C? -6 alkyl) 2-aminoalkoxy of C? _6, alkyl Ci-eS ( O) C 2 -6 alkoxy, N, N (Ci-β alkyl) 2 amino-N- (C?-6 alkyl) C alqu-6 alkylamino, N, N- (alkyl)
C? _6) 2-aminoalkylamino of C? -6-C? _6 alkyl, piperidin-1-ylalkyl of C? -6, homopiperidin-1-ylalkyl of Ci-e, N- (C? -6 alkyl) piperidin- 1-ylalkyl of C? -6, N- (Ci-e alkyl) homopiperidin-1-ylalkyl of C? _6, piperazin-1-ylalkyl of C? -6, 4-alkylpiperazine of C? -6-l- C] -6-alkyl, C6-6 homopiperazinyl-1-yl, C4-4-alkyl-homopiperazinyl, Ci-6-l-ylalkyl, C? -6 pyrrolidinylalkoxy, C? -6 piperidinylalkoxy, homopiperidinylalkoxy C? _6, N- (C? _6 alkyl) pyrrolidinylalkoxy of C? -6, N- (C? -6 alkyl) piperidinylalkoxy of C? -6, N- (Ci-e alkyl) homopiperidinylalkoxy of C? -6, C? -6 morpholinylalkoxy, C? _6 piperazinylalkoxy, N- (C? _6 alkyl) pi? Azinylalkoxy of C? -6, homopiperazinylalkoxy of C? -6, N- (Ci-e alkyl) homopiperazinylalkoxy C? -6, pyrrolidinyloxy, N- (C? -6 alkyl) pyrrolidinyloxy, piperidinyloxy, N- (C? -6 alkyl) piperidinyloxy, homopiperidinyloxy, N- (C? -6 alkyl) homopiperidinyloxy, morpholinylalkyl C6-C6-alkyl, C6-6 thiazolylalkoxy or Ci-e pyridylalkoxy; R 2 is hydrogen, C 4 alkyl or halo; R3 is hydrogen, C? _4 alkyl or halo; q is 0; R4 is phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by one or two of halo, trifluoromethyl, cyano, C? - alkyl, C? - alkoxy, -O- (C? -3 alkyl) ) -0-, N, N- (C? -4) 2amino alkyl, Ci-e alkanoylamino, C? -6 ~ N- (Ci-e alkyl) amino, phenyl (optionally substituted by one or two halo groups), furyl, azetidinyl, pyrrolidinyl, 3-pyrrolinyl, piperidino, homopiperidinyl, morpholino, piperazinyl, homopiperazinyl, N- (Ci-d alkyl) piperazinyl and N- (C6-6 alkyl) homopiperazinyl, or R4 is fluorenyl or dibenzofuranyl; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. According to a further preferred aspect of the invention, there is provided a compound of the Formula (I) wherein: the bicyclic ring formed by the fusion of the X ring to the 6-membered heteroaryl ring containing adjacent nitrogen within the Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolpyrimidinyl, oxazolpyrimidinyl, thiazolopyrimidinyl, purinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl; m is 0 or m is 1 and each R1 is independently hydroxy, halo, C6_6 alkyl, C6_6 alkoxy, C6_6S (0) n- alkyl (where n is 0-2), N , N- (C? -6-alkyl) 2-aminoalkyl of C? _6, N, N- (C? _6 alkyl) 2-carbamoylalkoxy of C? -6, N, N- (C? -6 alkyl) 2-aminoalkoxy of C ? -6, alkyl C? -6S (O) 2-C? -6 alkoxy, N, N (C? _6 alkyl) 2 amino- N- (C? _6 alkyl) C? -6 alkylamino, N , N- (Ci-e alkyl) 2-aminoalkylamino of C? -6-C? -6 alkyl, piperazin-1-ylalkyl of C? _6, 4-alkylpiperazine of C? -6-l-ylalkyl of C? -6, homopiperazinyl-1-ylalkyl of C? -6, 4-alkylhomopiperazinyl of C? -6-l-ylalkyl of C? -6, pyrrolidinylalkoxy of C? -6, piperidinylalkoxy of C? -6, N- (alkyl) of C6-6) pyrrolidinylalkoxy of C6-6, N- (C6-6 alkyl) piperidinylalkoxy of C6-6, C6-6 morpholinylalkoxy, C6-6 piperazinylalkoxy, N-
C? _6) piperazinylalkoxy of C? _6, homopiperazinylalkoxy of Ci-e,
N- (Ci-d alkyl) homopiperazinylalkoxy of C? -6, pyrrolidinyloxy, piperidinyloxy, morpholinylalkyl amino
C? -6-C? -5 alkyl or Ci-e pyridylalkoxy; R 2 is hydrogen, C 1-4 alkyl or halo; R3 is hydrogen, C1-4 alkyl or halo; q is 0; R 4 is phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by one or two of halo, cyano, C 4 alkyl, C 1-4 alkoxy,
N, N- (C 4 -4) alkyl 2-amino, piperidinyl, morpholino or piperazinyl; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. In a more preferred aspect of the invention there is provided a compound of the Formula (I) wherein: the bicyclic ring formed by the ring X fusion to the 6-membered heteroaryl ring containing adjacent nitrogen within the Formula (I) is furo [3, 2-d] pyrimidinyl, furo [2, 3-d] pyrimidinyl, thieno [3,2-d] pyrimidinyl, thieno [2,3-d] pyrimidinyl, pyrrol [3,2-d] pyrimidinyl , pyrrole [2, 3-d] pyrimidinyl, oxazole [5,4-d] pyrimidinyl, oxazole [4, 5-d] pyrimidinyl, thiazole [5,4-d] pyrimidinyl, thiazole [4, 5-d] pyrimidinyl] , purinyl, pyrido [2, 3-d] pyrimidinyl, pyrido [3,4-d] pyrimidinyl, pyrido [4, 3-d] pyrimidinyl, pyrido [3,2-d] pyrimidinyl, pyrimido [4,5-d] ] pyrimidinyl, pyrimido [5,6-d] pyrimidinyl or pteridinyl; is O or m is 1 and each R 1 is independently methyl, methoxy, methylthio, 2-diisopropylaminoethoxy, 3-diethylaminopropoxy, 3-morpholinopropoxy or 3-pyrrolidin-1-ylpropoxy; R2 is hydrogen, methyl, fluoro or chloro; R3 is hydrogen; q is 0; R 4 is phenyl optionally substituted by one or two groups selected from fluoro, chloro, trifluoromethyl, cyano, methyl, methoxy, ethoxy, methylenedioxy, N, N-dimethylamino, acetamido, N-methylmethanesulfonamido, phenyl, 4-fluorophenyl, 4- chlorophenyl, 2-furyl, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4- methylpiperazin-1-yl and 4-methylhomopiperazin-1-yl, or R 4 is pyridyl optionally a group substituted by N, N-dimethylamino, N, N-diethylamino, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin -l-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4-methylpiperazin-1-yl or 4-methylhomopiperazin-1-yl, or R 4 is 1-fluorenyl or dibenzofuran-4-yl; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. In a more preferred aspect of the invention there is provided a compound of Formula (I) wherein: the bicyclic ring formed by the ring X fusion to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is furo [3,2-d] pyrimidinyl, furo [2, 3-d] pyrimidinyl, thieno [3,2-d] pyrimidinyl, thieno [2,3-d] pyrimidinyl, pyrrol [3,2-d] pyrimidinyl, pyrrole [2, 3-d] pyrimidinyl, oxazole [5,4-d] pyrimidinyl, oxazole [4,5-dlpyrimidinyl, thiazole [5,4-d] pyrimidinyl, thiazole [4,5-d] irimidinyl, purinyl, pyrid [2,3-d] pyrimidinyl, pyrido [3,4-d] pyrimidinyl, pyrido- [4, 3-d] pyrimidinyl, pyrido [3,2-d] pyrimidinyl, pyrimido [4, 5-d] pyrimidinyl, pyrimido [5, 6-d] pyrimidinyl or pteridinyl; m is 0 or m is 1 and each R 1 is independently methyl, methoxy, methylthio, 2-diisopropylaminoethoxy, 3-diethylaminopropoxy, 3-morpholinopropoxy or 3-pyrrolidin-1-ylpropoxy; R2 is hydrogen, methyl, fluoro or chloro; R3 is hydrogen; q is 0; R 4 is pyridyl optionally substituted by a group N, N-dimethylamino, N, N-diethylamino, pyrrolidin-1-yl, piperidino or morpholino; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. In one aspect of the invention there is provided a compound of Formula (I) wherein: the bicyclic ring formed by the fusion of ring X to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is thien [3 , 2-d] pyrimidin-4-yl, thieno [2,3-d] pyrimidin-4-yl, thiazole [5,4-d] pyrimidin-7-yl, 6-purinyl, pyrido [2, 3-d] ] pyrimidin-4-yl, pyrido [3,4-d] pyrimidin-4-yl, pyrido [4, 3-d] pyrimidin-4-yl, pyrido [3,2-d] pyrimidin-4-yl or pteridin -4-ilo; m is 0 or m is 1 and R1 is methyl or methylthio; R2 is methyl; R3 is hydrogen; q is 0; R 4 is phenyl, 3-fluorophenyl, 4-cyanophenyl, 2-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-ethoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 3- (N, N-dimethylamino) phenyl, 3-acetamidophenyl, 3- (4-fluorophenyl) phenyl, 3- (2-furyl) phenyl, 3-pyrrolidin-1-ylphenyl, 3-morpholinophenyl, 3-fluoro-5-pyrrolidin-1-ylphenyl, 3- fluoro-5-piperidinophenyl, 3-fluoro-5-morpholiniphenyl or 3-morpholino-5-trifluoromethylphenyl, or R4 is 2-morpholinipyrid-4-yl, or R4 is 1-fluorenyl or dibenzofuran-4-yl; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. In a more preferred aspect of the invention there is provided a compound of Formula (I) wherein: the bicyclic ring formed by the ring X fusion to the adjacent nitrogen-containing 6-membered heteroaryl ring within Formula (I) is thieno [3,2-d] pyrimidin-4-yl, thieno [2,3-d] pyrimidin-4-yl, thiazol [5,4-d] pyrimidin-7-yl, pyrido [2,3-d] pyrimidine -4-yl, pyrido [3,4-d] pyrimidin-4-yl, pyrido [4, 3-d] pyrimidin-4-yl, pyrido [3,2-d] pyrimidin-4-yl or pteridin-4 -ilo; m is 0 or m is 1 and R1 is methyl or methylthio; R2 is methyl; R3 is hydrogen; q is 0; R 4 is 2-morpholinopyrid-4-yl; and R5 is hydrogen;
or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. Preferred compounds of the invention are those of Examples 1-3 or pharmaceutically acceptable salts or an in vivo cleavable ester thereof. An especially preferred compound of the invention is, for example, a compound of Formula (I) selected from: - 4- [2-methyl-5- (2-morpholinopyridine-4-carboxamido) -anilino] thieno [3 , 2-d] pyrimidine, 4- [2-methyl-5- (2-morpholinopyridin-4-carboxamido) anilino] irido [4, 3-d] pyrimidine, 4- [2-methyl-5- (2 -morpholinopyridine-4-carboxamido) anilino] pteridine and 6- [2-methyl-5- (2-morpholinopyridine-4-carboxamido) anilino] -purine; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. A suitable pharmaceutically acceptable salt of a compound of Formula (I) is, for example, an acid addition salt of a compound of Formula (I) which is sufficiently basic, for example an acid addition salt with an inorganic acid or organic such as hydrochloric, hydrobromic, sulfuric, trifluoroacetic, citric, or maleic acid; or, for example, a salt of a compound of the formula (I) which is sufficiently acidic, for example an alkali metal or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris- (2-hydroxyethyl) amine. Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see: a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Idder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5"Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); d) H. Bundgaard, et al. , Journal of Pharmaceutical Sciences, 77, 285 (1988); and e) N. Kakeya, et al. , Chem Pharm Bull, 32, 692 (1984). Examples of such prodrugs can be used to form in vivo cleavable esters of a compound of Formula (I). An in vivo cleavable ester of a compound of the Formula (I) which contains a carboxy group is, for example, a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the acid of origin. Pharmaceutically acceptable esters suitable for carboxy include alkoxymethyl esters of C? -6, for example methoxymethyl; alkanoyloxymethyl esters of C? _6, for example pivaloyloxymethyl; phthalidyl esters; C3-8 cycloalkoxycarbonyloxy esters of C? -6 alkyl, for example 1-cyclohexylcabonyloxyethyl; 1,3-dioxolan-2-ylmethyl esters, for example 5-methyl-l, 3-dioxolan-2-ylmethyl; and alkoxycarbonyloxyethyl esters of C? -6, for example 1-methoxycarbonyloxyethyl; and they can be formed in any carboxy group in the compounds of this invention. To use a compound of Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof, for the therapeutic treatment (including prophylactic treatment) of mammals including humans, they are usually formulated in accordance with the practice Pharmaceutical standard as a pharmaceutical composition. According to this aspect of the invention there is provided a pharmaceutical composition comprising a bicyclic compound of the Formula (I), or a pharmaceutically acceptable salt or in vivo cleavable ester thereof, as defined above in association with a pharmaceutically acceptable diluent or carrier. acceptable. The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, powders or dispersible granules, syrups or elixirs), for local use (for example as creams, ointments, gels or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example, as a sterile aqueous or oily solution for intravenous dosing) , subcutaneous, intramuscular or intramuscular as a suppository for rectal dosing). The compositions of the invention can be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, the compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and / or preservative agents. Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid.; binding agents such as starch, lubricating agents such as magnesium stearate, stearic acid or talc; preservatives such as ethyl or propyl p-hydroxybenzoate, and antioxidants, such as ascorbic acid. The tablet formulations may be uncoated or coated to modify their disintegration and subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and / or appearance, in any case, using conventional coating agents and well-known procedures in The technique. Compositions for oral use may be in the form of hard gelatine capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin or as soft gelatine capsules in which The active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil. Aqueous suspensions generally contain the active ingredient in finely pulverized form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl pyrrolidone, tragacanth gum and acacia gum; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate) or condensation product of ethylene oxide, with long-chain aliphatic alcohols, for example heptadecaethylene oxyketanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide, with partial esters derived from fatty acids and hexitol anhydrides, for example monooleate polyethylenesorbitan. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, antioxidants (such as ascorbic acid), coloring agents, flavoring agents, and / or sweetening agents (such as sucrose, saccharin, or aspartame). The oily suspensions can be formulated by suspending the active ingredient in a vegetable oil (such as peanut oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). may contain a thickening agent such as beeswax, hard wax, or cetyl alcohol, Sweetening agents such as those noted above, and flavoring agents may also be added to provide a pleasant oral preparation.These compositions may be preserved by the addition of such an antioxidant. as ascorbic acid, powders and dispersible granules suitable for the preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavoring and coloring agents may also be present. The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, such as olive oil or peanut oil, or a mineral oil, such as, for example, liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally occurring gums, such as acacia gum or tragacanth gum, naturally occurring phosphatides such as soy, lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides ( for example sorbitan monooleate) and condensation products of the partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavoring and preservative agents. The syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain an emollient, preservative, flavoring and / or coloring agent.
The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol. Suppository formulations can be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols. Local formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, can generally be obtained by formulating an active ingredient with a conventional locally acceptable vehicle or diluent using conventional procedures well known in the art. The compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30 μm or much less, the powder itself comprising the active ingredient alone or diluted with one or more carriers physiologically acceptable such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, one to 50 mg of active ingredient for use with a turbo inhaler device, such as is used for insufflation of the known agent sodium cromoglycate. The compositions for administration by inhalation may be in the form of a conventional pressurized aerosol arranged to distribute the active ingredient as an aerosol containing finely divided solid or droplets of liquid. Conventional aerosol propellants such as hydrocarbons or volatile fluorinated hydrocarbons can be used and the aerosol device is conveniently arranged to deliver a measured amount of the active ingredient. For additional information on the Formulation, refer to the reading of Chapter 25.2 of Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of the Editorial Board), Pergamon Press 1990. The amount of an active ingredient that is combined with one or more excipients for producing an individual dosage form will necessarily vary depending on the host treated and the particular route of administration.
For example, a formulation intended for oral administration to humans will generally contain, for example, 0.5 mg to 2 g of the active agent compound with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For additional information on Administration Routes and Dosage Regimens, refer to the reading of Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch, Chairman of Editorial Borad), Pergamon Press 1990. The size of the dose for therapeutic purposes or prophylactics of a compound of Formula (I) will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, in accordance with well-known principles of medicine. To use a compound of Formula (I) for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range of, for example, 0.5 mg to 75 mg per kg of body weight, preferably 0.5 mg, is received. at 40 mg per kg of body weight, administered if required in divided doses. In general, lower doses will be administered when a parenteral route is used. A) Yes, for example, for intravenous administration, a dose in the range of, for example, 0.5 mg to 30 mg per kg of body weight will generally be used. Similarly, for administration by inhalation, a dose in the range of, for example, 0.5 mg to 25 mg per kg of body weight will be used. However, oral administration is preferred. Particularly in the form of tablets. Typically, the unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention. The compounds of this invention can be used in combination with other drugs and therapies used in the treatment of affective states that would benefit from the inhibition of cytokines, in particular TNF and IL-1. For example, the compounds of Formula (I) could be used in combination with drugs and therapies used in the treatment of rheumatoid arthritis, asthma, irritable bowel disease, multiple sclerosis, AIDS, septic shock, ischemic heart disease, psoriasis and others. affective states mentioned earlier in this specification. For example, by virtue of their ability to inhibit cytokines, the compounds of Formula (I) are of value in the treatment of some inflammatory and non-inflammatory diseases that are currently treated with a non-steroidal anti-inflammatory drug cyclooxygenase inhibitor (NSAID). ) such as indomethacin, ketorolac, acetylsalicylic acid, ibuprofen, sulindac, tolmetin and piroxican. Co-administration of a compound of Formula (I) with an NSAID can result in a reduction in the amount of the last agent needed to produce a therapeutic effect. As a result, the likelihood of adverse side effects of the NSAID such as gastrointestinal effects is reduced. Thus according to a further feature of the invention there is provided a pharmaceutical composition comprising a compound of the Formula (I) or a pharmaceutically acceptable salt or in vivo cleavable ester thereof, together with or prepared with a non-steroidal anti-inflammatory agent inhibiting cyclooxygenase , and a pharmaceutically acceptable diluent or carrier. The compounds of the invention can also be used with anti-inflammatory agents, such as an inhibitor of the enzyme 5-lipoxygenase (such as those described in European Patent Applications Nos. 0351194, 0375368, 0375404, 0375452, 0375457, 0381375, 0385662 , 0385663, 0385679, 0385680). The compounds of Formula (I) can also be used in the treatment of conditions such as rheumatoid arthritis in combination with anti-arthritic agents such as gold, methotrexate, steroids and penicillinamine, and under conditions such as osteoarthritis in combination with steroids. The compounds of the present invention can also be administered in degradative diseases, for example osteoarthritis, with chondroprotective, anti-degradative and / or reparative agents such as Diacerhein, hyaluronic acid formulations such as Hyalan, Rumalon, Arteparon and glucosamine salts such as Antril. . The compounds of Formula (I) can be used in the treatment of asthma in combination with antiasthmatic agents such as bronchodilators and leukotriene antagonists. If formulated as a fixed dose such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active agents within their approved dosage range. Sequential use is contemplated when the combination formulation is inappropriate. Although the compounds of Formula (I) are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful where required to inhibit the effects of cytokines. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents. According to a further aspect of the present invention, a process is provided for preparing a compound of Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof, whose process (wherein G, R1, R2, R3, R4, R °, ring X , m and q are as defined for Formula (I) unless otherwise indicated) comprises: a) reacting an aniline of Formula (II):
with an acyl compound of Formula (III):
wherein L is a displaceable group as defined below; b) reacting an activated bicyclic heteroaryl ring of the Formula (IV): wherein L is a displaceable group as defined below, with an aniline of the Formula (V):
or c) for the preparation of a compound of the formula (I) wherein R 1 or a substituent on R 4 is C? -6 alkoxy or substituted C? -6 alkoxy, Ci-eS- alkyl, C-N-alkylamino ? -6, N, N- (C? -6) 2amino alkyl or substituted C? -6 alkylamino, the alkylation, conveniently in the presence of a suitable base as defined below, of a compound of the Formula (I) ) wherein R1 or a substituent on R4 is hydroxy, mercapto or amino as appropriate; and after that if necessary: i) converting a compound of the Formula (I) to another compound of the Formula (I); ii) eliminate any protective groups; and iii) forming a pharmaceutically acceptable salt or ester cleavable in vivo. The specific reaction conditions for the variants of the above process are as follows: For process variant a) A suitable displaceable group L is, for example, a halogen, an activated phenoxy group or a sulfonyloxy group, for example a chlorine , bromine, pentafluorophenoxy or methanesulphonyloxy or toluene-4-sulfonyloxy group. Especially the preferred displaceable groups are chloro and pentafluorophenoxy. The anilines of the Formula (II) and the acyl compounds of the Formula (III) can be reacted together in a suitable inert solvent or diluent, for example dichloromethane, acetonitrile, butanol, tetramethylsulphone, tetrahydrofuran, 1,2-dimethoxyethane, N, N-dimethylformamide, N, N-dimethylacetamide or N-methylpyrrolidin-2-one, optionally in the presence of a base such as an alkali metal or alkaline earth metal carbonate, alkoxide or hydroxide, for example sodium carbonate or potassium carbonate, or , such as, an organic amine base, for example, pindine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo [5.4.0] undec-7-ene, and at a temperature in the range of, for example, 0 ° to 50 ° C, conveniently at or near room temperature. The anilines of Formula (II) can be prepared according to the following scheme: Q is -NH2 or, if R2 and R3 are not identical and a specific stereo reaction is desired, Q can be amino protected by a suitable protecting group (such as those defined later) or nitro. After the above reaction, the protecting group is removed, or the nitro group is reduced (for example with iron powder and acetic acid) to generate an aniline of the Formula (II). The activated heteroaryls of the Formula (IV) are known compounds, are commercially available or are prepared by processes known in the art. For example, where L is chloro or pentafluorophenoxy, compounds of Formula (IV) can be prepared by the following scheme:
(1VC) For process variant b) A suitable displaceable L group as defined above. The activated heteroaryl of the formula (IV) and anilines of the formula (V) can be reacted together in the presence of a protic solvent, for example, isopropanol, in the presence of an acid, for example hydrogen chloride gas in ether diethyl, or hydrochloric acid, and at a temperature in the range of, for example, 0 ° to 150 ° C, conveniently at or near reflux. The anilines of Formula (V) are known compounds, are commercially available, or are made by processes known in the art. For example, the anilines of Formula (V) can be prepared according to the following scheme:
(VA) (VB)
where Q is as defined above. The compounds of the formulas (IIB), (III), (VA) and
(VB) are known compounds, are commercially available or are prepared by processes known in the art. For variant c) of the process A suitable alkylating agent is, for example, any agent known in the art for the alkylation of hydroxy in alkoxy or substituted alkoxy, or for the alkylation of mercapto in alkylthio, or for the alkylation of amino in alkylamino or substituted alkylamino, for example an alkyl or alkyl halide substituted, for example a C? -6 alkyl chloride, bromide or iodide or substituted C? -6 alkyl chloride, bromide or iodide, in the presence of a suitable base as defined below, in an inert solvent or diluent adequate as defined above for variant a) of the process. A suitable base is, for example, an alkali metal or alkaline earth metal carbonate, alkoxide, hydroxide or hydride, for example sodium carbonate, potassium carbonate, sodium ethoxide, potassium butoxide, sodium hydroxide, potassium hydroxide, hydride sodium or potassium hydride, or an organometallic base such as an alkyl lithium, for example n-butyllithium, or a dialkylamino lithium, for example di-isopropylamide-lithium, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo [5.4.0] undec-7-ene. The reaction is conveniently carried out at a temperature in the range of, for example, 10 to 150 ° C, preferably in the range of 20 to 80 ° C.
Any necessary protecting groups can generally be selected from any of the groups described in the literature or known to the skilled chemist as is appropriate for the protection of the group in question and can be introduced by conventional methods. The protecting groups can be removed by any convenient method as described in the literature or known to the skilled chemist as is appropriate for the removal of the protective group in question, such methods being selected in such a way as to effect removal of the protecting group with minimal disturbance. of the groups in another part of the molecule. Specific examples of protecting groups are given subsequently for reasons of convenience in which "lower", as in, for example, lower alkyl, means that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods are given for the removal of protecting groups that are given subsequently are equally non-exhaustive. The use of protective agents and methods for deprotection not specifically mentioned are, of course, within the scope of the invention. A carboxy protecting group may be the residue of an aliphatic or arylaliphatic alcohol which forms ester or of a lower one (for example acetyl); lower alkoxycarbonyl groups (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl groups (for example allyloxycarbonyl); lower alkoxycarbonyl groups (for example benzoyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl); trialkylsilyl lower (for example trimethylsilyl, tert-butyldimethylsilyl) and aryl lower alkyl groups (for example benzyl). Examples of protective amino groups include formyl, aralkyl groups (for example benzyl and substituted benzyl, p-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-p-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl (for example allyloxycarbonyl); lower arylalkoxycarbonyl groups (for example benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, trialkylsilyl (for example trimethylsilyl and tert-butyldimethylsilyl) alkylidene (for example methylidene), substituted benzylidene and benzylidene groups. of hydroxy and amino protecting groups include, for example, acid, basic, metallic, or enzymatically catalyzed hydrolysis for groups such as p-nitrobenzyloxycarbonyl, ester forming silanol (preferably containing 1-20 carbon atoms or silanol). carboxy protecting groups include straight or branched chain C? _?? alkyl groups (eg, isopropyl, tert-butyl), lower alkoxy-lower alkyl groups (eg methoxymethyl, ethoxymethyl, isobutoxymethyl), lower aliphatic acyloxy-lower alkyl groups , (for example acetoxymethyl, propionyloxymethyl, butyryloxymethyl, piva loyloxymethyl); lower alkoxycarbonyloxy-lower alkyl groups (for example 1-methoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl); lower arylalkyl groups (for example benzyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, benzhydryl and phthalidyl); tri (lower alkyl) silyl groups (for example trimethylsilyl and tert-butyldimethylsilyl); tri (lower alkyl) silyl-lower alkyl groups (for example trimethylsilylethyl); and alkenyl groups of C? _6 (for example allyl and vinylethyl). Particularly suitable methods for the removal of carboxyl protecting groups include for example acid, basic, metallic or enzymatically catalyzed hydrolysis. Examples of hydroxy protecting groups include lower alkyl groups (for example tert-butyl), lower alkenyl groups (for example allyl); alkanoyl groups hydrogenation for groups such as benzyl and photolytically for groups such as o-nitrobenzyloxycarbonyl. Reference is made to the reading of Advanced Organic Chemistry, 4th Edition, by Jerry March, published by John Wiley & amp; amp;; Sons 1992, for general guidance on reaction conditions and reagents. Reference is made to the reading of Protective Groups in Oganic Synthesis, 2nd Edition, by Green et al. , published by John Wiley & Sons for general guidance on protective groups. According to a further aspect of the present invention there is provided a bicyclic compound of the Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, for use in a method for treating the human body or animal for therapy. In a further aspect of the present invention there is provided a bicyclic compound of the Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, for use as a medicament. In a further aspect, the present invention provides the use of a bicyclic compound of the Formula(I), or a pharmaceutically acceptable salt or in vivo cleavable ester thereof as defined above, or the use of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine in the manufacture of a drug for use in the treatment of diseases or medical conditions mediated by cytokines. In a further aspect the present invention provides a method for treating diseases or medical conditions mediated by cytokines which comprises administering to a warm-blooded animal an effective amount of a bicyclic compound of the Formula (I) or a pharmaceutically acceptable salt or an unfolding ester. in vivo thereof as defined above, or of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine. In a further aspect, the present invention provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, or the use of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine in the manufacture of a medicament for use in the treatment of diseases or medical conditions mediated by TNF, IL-1, IL-6 or IL-8. In a further aspect, the present invention provides a method for treating diseases or medical conditions mediated by TNF, IL-1, IL-6 or IL-8 which comprises administering to a warm-blooded animal an effective amount of a compound of the Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, or of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine. In a further aspect, the present invention provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, or the use of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4,3-d] pyrimidine in the manufacture of a medicament for use in the treatment of diseases or medical conditions mediated by TNF. In a further aspect, the present invention provides a method for treating diseases or medical conditions mediated by TNF which comprises administering to a warm-blooded animal an effective amount of a compound of the Formula (I), or a pharmaceutically acceptable salt or an ester in vivo cleavable thereof as defined above, or the compound 7-amino-4- (3-acetamidoanilino) pyrido [4-3d] pyrimidine. In a further aspect the present invention provides the use of a compound of the Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, or the use of the 7-amino-4- ( 3-acetamidoanilino) pyrido [4, 3-d] pyrimidine in the manufacture of a medicament for use in the inhibition of TNF, IL-1, IL-6 or IL-8. In a further aspect, the present invention provides a method for inhibiting TNF, IL-1, IL-6 or IL-8 comprising administering to a warm-blooded animal an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, or of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine. In a further aspect, the present invention provides the use of a compound of the Formula (I), or a pharmaceutically acceptable salt or a cleavable ester thereof in vi thereof as defined above, or the use of the compound 7-amino-4 - (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine in the manufacture of a medicament for use in inhibiting TNF. In a further aspect, the present invention provides a method for inhibiting TNF which comprises administering to a warm-blooded animal an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or in vivo cleavable ester thereof as was defined above, or of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4-3d] pyrimidine. In an additional aspect, the present invention provides the use of a compound of the Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, or the use of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine in the manufacture of a medicament for use in the treatment of diseases or medical conditions mediated by p38 kinase. In a further aspect, the present invention provides a method for treating diseases or medical conditions mediated by p38 kinase which comprises administering to a warm-blooded animal an effective amount of a compound of the Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, or of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4-3d] pyrimidine. In a further aspect, the present invention provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof as defined above, or the use of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine in the manufacture of a medicament for use in the production of an inhibitory effect of p38 kinase. In a further aspect the present invention provides a method for providing an inhibitory effect of p38 kinase which comprises administering to a warm-blooded animal an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or a splittable ester in alive thereof as defined above, or of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine. In a further aspect, the present invention provides the use of a compound of the Formula (I), or a pharmaceutically acceptable salt or a cleavable ester thereof in vi thereof as defined above, or the use of the compound 7-amino-4 - (3-acetamidoanilino) pyrido [4,3-d] pyrimidine in the manufacture of a medicament for use in the treatment of rheumatoid arthritis, asthma, irritable bowel disease, multiple sclerosis, AIDS, septic shock, ischemic heart disease or psoriasis. The following biological tests and Examples serve to illustrate the present invention. Biological Tests The following tests can be used to measure the inhibitory effects of p38 kinase, TNF inhibitors and anti-arthritic compounds of the present invention: Enzyme test in vitro The ability of the compounds of the invention to inhibit the p38 enzyme was assessed kinase The activity of the particular test compounds against each of the p38a and p38β isoforms of the enzyme was determined.
Human recombinant MKK6 (Accession number GenBank G1209672) was isolated from the clone of Image 45578 (Genomics, 1996, 33, 151) and used to produce protein in the form of a GST fused protein in a pGEX vector using procedures analogous to those described by J. Han et al. , Journal of Biological Chemistry, 1996, 271, 2886-2891. P38a (GenBank Accession Number G529039) and p38β (GenBank Accession Number G1469305) were isolated by PCR amplification of human lymphoblastoid cDNA (GenBank accession number GM1416) and human fetal brain cDNA [synthesized from mRNA (Clontech, Catalog No. 6525-1) using a Gibco writing cDNA synthesis kit respectively using oligonucleotides designed for the 5 'and 3' ends of the human p38a and p38β genes using methods analogous to those described by J. Han et al. ., Biochimica et Biophysica Acta, 1995, 1265, 224-227 and Y. Jiang et al., Journal of Biological Chemistry, 1996, 271, 17920-17926. Both isoforms of the p38 protein were expressed in e coli in PET vectors. Recombinant human p38a and p38ß isorfornas were produced as proteins labeled 6His, 5 'c-myc. Both MKK6 and p38 proteins were purified using standard protocols: GST MKK6 was purified using a glutathione sepharose column and p38 proteins were purified using nickel chelated columns.
The p38 enzymes were activated before use by incubation with MKK6 for 3 hours at 30 ° C. MKK6 expressed non-activated coli retained sufficient activity to fully activate both isoforms of p38. The activation incubation comprises p38a (lOμl of lOmg / ml) or p38β (lOμl of 5mg / ml) together with MKK6 (lOμl of lmg / ml), 'kinase regulator * [lOOμl; pH 7.4 regulator comprising Tris (50mM), EGTA (0.1mM), sodium orthovanadate (0.1mM) and β-mercaptoethanol (0.1%)] and MgATP (30μl of 50mM Mg (0C0CH3) 2 and 0.5mM ATP). This produces enough p38 enzyme activated for 3 microtiter plates. The test compounds were solubilized in DMSO and lOμl of a sample diluted 1:10 in a 'kinase regulator' were added to a well in a microtiter plate. For the individual dose test, the compounds were tested at 10 μM. 'Kinase Test Mix' [30μl; which comprises Protein
Basic Myelin (Gibco BRL catalog No. 1322B-010, one ml of a 3.33 mg / ml solution in water), activated p38 enzyme
(50μl) and 'Kinase Regulator' (2ml)] was then added followed by 'ATP Marked1 [lOμl; comprising 50μM ATP, 0.1μCi33P ATP (Amersham International catalog No. BFIOOO) and 50mM Mg (OCOCH3) 2]. Plates were incubated at room temperature with gentle shaking. The plates containing p38a were incubated for 90 minutes and the plates containing p38β were incubated for 45 minutes. Incubation was stopped by the addition of 50μl of 20% trichloroacetic acid TCA). The precipitated protein was phosphorylated by p38 kinase and the test compounds were assessed for their ability to inhibit this phosphorylation. The plates were filtered using a Canberra Packard Unifilter and washed with 2% TCA, dried overnight and counted on a Top Count scintillation counter. The test compounds were initially tested at a single dose and the active compounds were retested to allow IC5 values to be determined. In vitro tests based on cells (i) PBMC The ability of the compounds of this invention to inhibit the production of TNFα was assessed using human peripheral blood mononuclear cells that synthesize and secrete TNFα when stimulated with lipopolysaccharide. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized human blood (10 units / ml heparin) by density centrifugation (Lymphoprep ™, Nycomed). The mononuclear cells were resuspended in a culture medium [RPMI 1640 medium
(Gibco) supplemented with 50 units / ml of penicillin,
50μg / ml streptomycin, 2mM glutamine and 1% heat-inactivated human AB serum (Sigma H-1513)]. The compounds were solubilized in DMSO at a concentration of 50mM, were diluted in a 1: 100 culture medium and subsequently serial dilutions were made in a culture medium containing 1% DMSO. The PBMCs (2.4xl05 cells in 160μl of culture medium). They were incubated with 20μl of various concentrations of test compound (cultures in triplicate) or 20μl of a culture medium containing 1% DMSO (control well) for 30 minutes at 37 ° C in a humidified incubator (5% C02 / 95% air) (Falcon 3072; 96 well flat bottom tissue culture plates). 20 μl of lipopolysaccharide [LPS E. Coli 0111.B4 (Sigma L-4130), final concentration of 10 μg / ml] solubilized in a culture medium was added to the appropriate wells. 20μl of a culture medium was added to control wells of a "medium alone". Six "LPS alone" and four controls of a "medium alone" were included in each 96-well plate. Various concentrations of a known inhibitor of TNFa were included in each test, ie an inhibitor of the PDE Type IV enzyme (for example see Semmler, J. Wachtel H. and Endres, S., Int. J. Immunopharmac. (1993) , 15 (3), 409-413) or an inhibitor of proTNFa convertase (for example, see, McGeehan, GM et al., Nature (1994) 370, 558-561). The plates were incubated for 7 hours at 37 ° C (humidified incubator) after which lOOμl of the supernatant from each well was removed and stored at -70 ° C (96 well round bottom plates, Corning 25850). TNFa levels were determined in each sample using ELISA to human TNFa (see W092 / 10190 and Current Protocols in
Molecular Biology, vol 2 by Frederick M. Ausbel et al., John
Wiley and Sons Inc.). % inhibition = (single-medium LPS only) - (test-medium concentration alone) X 100 (single-medium LPS only) (ii) Total Human Blood The ability of the compounds of this invention to inhibit the production of TNFa was also assessed on a human total blood test. Total human blood secretes TNFα when stimulated with LPS. This property of blood forms the basis of a test that is used as a secondary test for compounds that profile as active in the PBMC test. Heparinized human blood (10 units / ml) was obtained from volunteers. 160μl of whole blood was added to 96-well round bottom plates (Corning 25850). The compounds were solubilized and serially diluted in RPMI 1640 medium (Gibco) supplemented with 50 units / ml penicillin, 50μg / ml streptomycin and 2mM glutamine, as detailed above. 20μl of each test concentration was added to the appropriate wells (triplicate cultures). 20μl of an RPMI 1640 medium supplemented with antibiotics and glutamines was added to the control wells. The plates were incubated for 30 minutes at 37 ° C (humidified incubator), before the addition of 20 μl of LPS (final concentration of 10 μg / ml). An RPMI 1640 medium was added to the control wells. Six controls of "LPS alone" and four of a "medium alone" were included in each plate. A known inhibitor of synthesis / secretion of TNFa was included in each test. The plates were incubated for six hours at 37 ° C (humidified incubator). Plates were centrifuged (2000 rpm for 10 minutes) and lOOμl of plasma was removed and stored at -70 ° C (Corning plates 25850). TNFa levels were measured by ELISA (see WO92 / 10190 and Current Protocols in Molecular Biology, vol. 2 by Frederick M. Ausbel et al., John Wiley and Sons Inc.). The paired antibodies that were used in the ELISA were obtained from R & D Systems (anti-human TNFa coating antibody number MAB610, antibody detecting biotinylated TNFα biotinylated BAF210). Ex vivo / In vivo titration The ability of the compounds of this invention as ex vivo TNFa inhibitors was assessed in the rat or mouse. Briefly, groups of male Wistar Alderley Park (AP) rats (180-210g) were dosed with compound (6 rats) or drug vehicle (10 rats) by the appropriate route, for example peroral (po), intraperitoneal (ip) or subcutaneous
(s.c.) ninety minutes later the rats were sacrificed using an increasing concentration of CO 2 and they were bled by means of the posterior vena cava in 5 units of sodium heparin / ml of blood. The blood samples were immediately placed on ice and centrifuged at 2000 rpm for 10 minutes at 4 ° C and the harvested plasmas were frozen at -20 ° C for subsequent testing on their effect on TNFa production by human blood stimulated by LPS. . The rat plasma samples were thawed and 175 μl of each sample was added to a layout format pattern on a 96 well round bottom plate (Corning 25850). 50μl of heparinized human blood were then added to each well, mixed and the plate incubated for 30 minutes at 37 ° C (humidified incubator). LPS (25μl, final concentration of 10μg / ml) was added to the wells and incubation continued for an additional 5.5 hours. The control wells were incubated with 25μl of a single medium. The plates were then centrifuged for 10 minutes at 2000 rpm and 200μl of the supernatants were transferred to a plaque.
96 wells and were frozen at -20 ° C for subsequent analysis of TNF concentration by ELISA. The analysis is data by software calculations dedicated to each compound / dose:% inhibition of TNFa = Medium TNFa (Mean TNFa-Controls (treated) x 100 Mean TNFa (Controls) Alternatively, mice could be used instead of rats in the procedure Previous: Testing as an anti-arthritic agent The activity of a compound as an antiarthritic agent was tested as follows: It was shown by Trentham et al. [1] that native type II collagen soluble in acid is arthritogenic in rats.; caused polyarthritis when administered in incomplete Freunds adjuvant. This is now known as collagen-induced arthritis (CIA) and the same conditions can be induced in mice and primates. Recent studies have shown that anti-TNF monoclonal antibodies [2] and fused IgG-receptor proteins of TNF [3] improve the established CIA indicating that TNF plays a major role in the pathophysiology of CIA. In addition, the remarkable reported efficiency for anti-TNF monoclonal antibodies in recent clinical trials of rheumatoid arthritis indicates that TNF plays a major role in this chronic inflammatory disease. Thus CIA in DBA / 1 mouse as described in references 2 and 3 is a tertiary model that can be used to demonstrate the anti-arthritic activity of a compound. See also reference 4. 1. Trentham, D.E. et al. , (1977) J. Exp. Med., 146, 857. 2. Williams, R.O. et al. , (1992) Proc. Natl. Acad. Sci., 89, 9784. 3. Williams, R.O. et al. , (1995) Immunology, 84, 433. 4. Badger, M. B. et al. , (1996) The Journal of Pharmacology and Experimental Therapeutics, 279, 1453-1461.
Although the pharmacological properties of the compounds of Formula (I) vary with the structural change as expected, in general a compound of Formula (I) gives about 30% inhibition of p38a and / or p38β at concentrations up to 10. μM and over 30% inhibition in the PBMC test at concentrations of up to 50 μM. Physiological toxicity was not observed to be unacceptable at the effective dose of the tested compounds of the present invention. As an example: -
Examples The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise indicated: - (i) the operations were carried out at room temperature, i.e. in the range of 17 to 25 ° C and under an atmosphere of an inert gas such as argon unless otherwise indicated; (ii) the evaporations were carried out by rotary vacuum evaporation and the processing procedures were carried out after the removal of the residual solids by filtration; (iii) column chromatography (by the instantaneous procedure) was performed on silica Merck Kieselgel (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) or reverse phase silica obtained from E. Merck, Darmstadt,
Germany; (iv) the returns when present are given for illustration only and are not necessarily the maximum obtainable; (v) in general, the final products of Formula (I) have satisfactory microanalyses and their structures were confirmed by nuclear magnetic resonance (NMR) and / or mass spectrum techniques; the fast atom bombardment (FAB) mass spectrum data were obtained using a Platform spectrometer and, where appropriate, positive ion data or negative ion data were collected; the chemical change values of NMR were measured on the delta scale [the proton magnetic resonance spectra were determined using a Varian Gemini 2000 spectrometer operating at a 300 MHz field strength or an AM250 spectrometer operating at a field strength of 250 MHz ]; the following abbreviations have been used: s, simple; d, double; t, triple; m, multiple; br, broad; Unless otherwise indicated, the solvent used was deuterated dimethylsulfoxide (DMS0-d6); Example 1 4- [2-Methyl-5- (2-morpholinopyridine-4-carboxamido) anilino] -thieno [3,2-d] pyrimidine A mixture of N- (3-amino-4-methylphenyl) -2-morpholinopyridine 4-carboxamide (0.312 g), 4-chlorothieno [3,2-d] pyrimidine (PCT patent application W095 / 19774; 0.171 g), triethylamine (0.15 ml) and N, N-dimethylformamide (5 ml) was stirred and heated at 120 ° C for 36 hours. The mixture was cooled to room temperature and poured into water. The resulting precipitate was isolated and purified by column chromatography on silica using a 19: 1 mixture of ethyl acetate and methanol as eluent. Thus, the title compound was obtained as a solid (0.216 g, 48%); NMR: 2.14 (s, 3H), 3.51
(m, 4H), 3.69 (m, 4H), 7.08 (d, 1H), 7.21 (s, 1H), 7.29 (d,
1H), 7.37 (d, 1H), 7.68 (d, 1H), 7.74 (s, 1H), 8.08 (d, 1H),
8. 26 (d, 1H), 8.43 (s, 1H), 9.48 (s, 1H), 10.29 (s, 1H);
Mass: M + H + 447. The N- (3-amino-4-methylphenyl) -2-morpholinopyridine-4-carboxamide used as an initial material was obtained as follows: - Triethylamine (31.8 ml) was added to a stirred mixture of 4-methyl-3-nitroaniline (15.8 g), 2-chloropyridine-4-carbonyl chloride (20 g) and methylene chloride (1 liter) and the resulting mixture was stirred at room temperature for 16 hours. The precipitate was isolated, washed with a saturated solution of aqueous sodium bicarbonate and with methylene chloride and dried under vacuum at 40 ° C. Thus, 2-chloro-N- (4-methyl-3-nitrophenyl) pyridine-4-carboxamide (10.2 g) was obtained. The organic filtrate was washed with a saturated aqueous sodium bicarbonate solution, dried (MgSO 4) and evaporated. The residue was triturated under methylene chloride and the resulting solid was isolated and dried under vacuum at 40 ° C. Thus, a second culture (8.13 g) of 2-chloro-N- (4-methyl-3-nitrophenyl) pyridine-4-carboxamide was obtained.; NMR: 2.48 (s, 3H), 7.51 (d, 1H), 7.86 (m, 1H), 7.96 (m, 2H), 8.49 (m, 1H), 8.64 (m, 1H), 10.85 (s, 1H); Mass: M + H + 292 and 294. A mixture of the pyridine-4-carboxamide thus produced and morpholine (250 ml) was stirred and heated at 100 ° C for 18 hours. The mixture was poured into water (250 ml) and stirred for 10 minutes. Methylene chloride (30 ml) was added and the resulting mixture was stirred for 30 minutes. The resulting solid was isolated, washed with methylene chloride and dried in a vacuum oven at 40 ° C for 18 hours. Thus, N- (4-methyl-3-nitrophenyl) -2-morpholinopyridine-4-carboxamide (17.34 g) was obtained; NMR: 2.48 (s, 3H), 3.52 (m, 4H), 3.71 (m, 4H), 7.1 (d, 1H), 7.25 (s, 1H), 7.49 (d, 1H), 7.97 (m, 1H) , 8.29 (m, 1H), 8.49 (m, 1H), 10.62 (s, 1H); Mass: M + Hx 343.
A mixture of a portion (8.5 g) of the obtained material, 5% palladium on carbon catalyst (0.85 g) and methanol (600 ml) was stirred under a pressure atmosphere of hydrogen gas for 18 hours. Methylene chloride (400 ml) was added and the reaction mixture was filtered through the diatomacea. The filtrate was evaporated to give N- (3-amino-4-methylphenyl) -2-morpholinopyridine-4-carboxamide, (6.41 g), NMR: 2.01 (s, 3H), 3.52 (m, 4H), 3.73 (m, 4H), 4.83 (s, 2H), 6.7 (d, 1H), 6.84 (d, 1H), 7.04-7.08 (m, 2H), 7.2 (s, 1H), 8.2 (d, 1H), 9.95 (s) , 1 HOUR); Mass: M + H + 313. EXAMPLE 2 4- [2-Methyl-5- (2-morpholinopyridine-4-carboxamido) anilino] -5-methylthieno [2,3-d] pyrimidine. A 1M solution of hydrogen chloride in the diethyl ether (0.2 ml) was added to a mixture of N- (3-amino-4-methylphenyl) -2-morpholinopyridine-4-carboxamide, (0.056 g), 4-chloro-5-methylthiene [2, 3-d] pyrimidine [Maybridge Chemica Company, Trevillet, Tintagel, Cornwall, PL34 0HW, GB; 0.037 g) and isopropanol (2 ml) and the reaction mixture was stirred and heated at 88 ° C for 18 hours. The reaction mixture was cooled to room temperature and the precipitate was isolated and washed in turn with isohexane and diethyl ether. Thus, the title compound (0.021 g) was obtained; Mass: M + H + 461.
Example 3 Using an analogous procedure to that described in Example 2, the appropriate 4-chloroheterocycle (obtained, unless otherwise indicated from Maybridge Chemical Company, Trevillet, Tintagel, Cornwall, PL34 OHW, GB) was reacted with the appropriate aniline to give the compounds described in the following Table.
Notes a) The product gave the following data: Mass: M + H + 461. b) The 4-chlorothieno [2,3-d] pyrimidine used as an initial material was obtained as described in the PCT patent application WO 95 / 19774. The product gave the following data: Mass: M + H + 447.
c) The product gave the following data: Mass: M + H + 494. d) The product gave the following data: Mass: M + H + 442. The 4-chloropyrido [4, 3-d] pyrimidine used as an initial material obtained as follows: - A mixture of pyrido [4, 3-d] pyrimidin-4 (1H) -one
(PCT Patent Application WO 95/19774; 0.03 g) and thionyl chloride (2 ml) was stirred and heated to reflux for
4 hours. The reaction mixture was cooled to room temperature and evaporated to give the required starting material which was used without further purification. e) The product gave the following data: Mass: M + H + 442. The 4-chloropyrido [2,3-d] pyrimidine used as an initial material was obtained as follows: - A mixture of pyrido [2, 3-d] pyrimidin-4 (1H) -one
(PCT Patent Application WO 95/19774; 0.03 g) and thionyl chloride (2 ml) was stirred and heated to reflux for 4 hours. The reaction mixture was cooled to room temperature and evaporated to give the required starting material which was used without further purification. f) The product gave the following data: Mass: M + H + 443. g) The product gave the following data: NMR: 2.18 (s, 3H), 3.52 (m, 4H), 3.75 (m, 4H), 7.09 ( m, 1H), 7.22 (m, 2H), 7.55 (m, 1H), 7.84 (broad s, 1H), 8.18 (broad s, 1H), 8.24 (m, 2H), 9.14 (broad s, 1H), 10.26 (s, 1H); Mass: M + H + 431.
Example 4 Pharmaceutical Compositions The following illustrates representative pharmaceutical dosage forms of the invention as defined herein (the active ingredient being called "Compound X"), for therapeutic or prophylactic use in humans: (a) Table I mg / tablet Compound X 100 Lactose Ph.Eur 182.75 Croscarmellose sodium 12.0 Corn starch paste (5% weight / volume paste) 2.25 Magnesium stearate 3.0 (b) Tablet II mg / tablet Compound X 50 Lactose Ph.Eur 223.75 Croscarmellose sodium 6.0 Corn starch 15.0 Polyvinylpyrrolidone (paste at 5% w / v) 2.25 Magnesium stearate 3.0 (c) Tablet III mg / tablet Compound X 1.0 Lactose Ph.Eur 93.25 Croscarmellose sodium 4.0 Corn starch paste (paste at 5% w / v) 0.75 Magnesium stearate 1.0 (d) Capsule mg / capsule Compound X 10 Lactose Ph.Eur 488.5 Magnesium 1.5 (e) Injection I (50 mg / ml) Compound X 5.0% w / v Sodium hydroxide solution 1 M 15.0% volume / volume 0.1M hydrochloric acid (to adjust pH to 7.6) Polyethylene glycol 400 4.5% w / v Water for injection up to 100%
(f) Injection II (10 mg / ml) Compound X 1.0% w / v Sodium Phosphate BP 3.6% w / v 0.1M sodium hydroxide solution 15.0% volume / volume
Water for injection up to 100% (g) Injection III (lmg / ml, regulated at pH6) Compound X 0.1% w / v Sodium Phosphate BP 2.26% w / v Citric acid 0.38% w / v Polyethylene glycol 400 3.5% w / v Water for injection up to 100% (h) Aerosol I mg / ml Compound X 10.0 Sorbitan triolate 13.5 Trichlorofluoromethane 910.0 Dichlorodifluoromethane 490.0 (i) Aerosol II mg / ml Compound X 0.2 Sorbitan triolate 0.27 Trichlorofluoromethane 70.0 Dichlorodifluoromethane 280.0 Dichlorotetrafluoroethane 1094.0 (j) Aerosol III mg / ml Compound X 2.5 Sorbitan triolate 3.38 Trichlorofluoromethane 67.5 Dichlorodifluoromethane 1086.0 Dichlorotetrafluoroethane 191.6 (k) Aerosol IV mg / ml Compound X 2.5 Lecithin from Soya 2.7 Trichlorofluoromethane 67.5 Dichlorodifluoromethane 1086.0 Dichlorotetrafluoroethane 191.6 (1) Ointment ml Compound X 40 mg Ethanol 300 μl Water 300 μl l-Dodecylazacycloheptane-2-one 50 μl Propylene glycol up to 1 ml Note The above formulations p They can be obtained by conventional procedures well known in the pharmaceutical art. Tablets (a) - (c) can be enteric coated by conventional means, for example to provide a cellulose acetate phthalate coating. The aerosol formulations (h) - (k) may be used in conjunction with standard metered dose aerosol dispensers, and the sorbitan triolate suspension agents and soy lecithin may be replaced by an alternative suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate, or oleic acid.
Claims (12)
- CLAIMS 1. A bicyclic compound of the formula (I) characterized in that: G is N, CH or C (CN); ring X is a 5 or 6 membered fused heteroaryl ring containing 1, 2 or 3 heteroatoms selected from oxygen, sulfur and nitrogen; m is 0, 1 or 2; R1 is hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulfamoyl, Ci-e alkyl, C2-6 alkenyl, C2_6 alkynyl, C6_6 alkoxy, -O- ( C? -3) -O-alkyl of Ci-eS (O) p- (wherein n is 0-2), N-alkylamino of C? -6, N, N- (C? -6 alkyl) ) 2-amino, C6-6 alkoxycarbonyl, N-alkylcarbamoyl of Ci-e, N, N- (Ci-e) alkylcarbamoyl, C2-6 alkanoyl, C6-6 alkanoyloxy, C6-6 alkanoylamino , N-alkylsulfoyl sulphonyl of C? -6, N, N- (alkyl of d-6) 2sulfamoyl, alkylsulfonylamino of C? -6, alkylsulfonyl of C? -6-N- (alkyl of Ci-β) amino, or R1 is of Formula (IA): A- (CH2) PB- (IA) wherein A is halo, hydroxy, C? -6 alkoxy, Ci-dS alkyl (0) n- (where n is 0-2), cyano, amino, N-alkylamino of C? -6, N, N- (C? -6-alkyl) 2-amino, carboxy, C? -6-alkoxycarbonyl, carbamoyl, N-alkylcarbamoyl of C? _6 or N, N- (C? -6) 2-carbamoyl alkyl, p is 1-6, and B is a bond, oxy, imino,
- ? T- (Ci-e) imino alkyl or -C (0)? H-, with the proviso that p is two or more unless B is a bond or -C (0)? H-, or R1 is of Formula (IB): D-E- (IB) wherein D is aryl, heteroaryl or heterocyclyl, and E is a bond, C6-6 alkylene, C6-6 alkyleneoxy, oxy, imino, N- (alkyl) Ci-e) imino, C? -6 alkyleneimino, N- (Ci-e-alkyl) -C6-6alkyleneimino, C? -6-alkylene-C6-6alkylene, C6-6-alkylene-alkyleneimino of Ci-e, N- (C? -6 alkyl) -alkyleneimino of C? -6-alkylene of C? _6, -C (0)? H-, -S02? H-, -? HS02- or alkanoyl of C2-6, and any aryl, heteroaryl or heterocyclyl group in a R1 group may be optionally substituted with one or more groups selected from hydroxy, haloC6 alkyl, C6-6 alkoxy, carboxy, alkoxycarbonyl C? -6, carbamoyl, N-alkylcarbamoyl of C? -6, N- (C? -6) alkylcarbamoyl, C2-6 alkanoyl, amino, N-alkylamino of C? -6 and N, N- ( C? -6) 2amino alkyl, and any heterocyclyl group in a R1 group may be optionally substituted with one or two oxo or thioxo substituents, and any of the R1 groups defined above that comprise a CH2 group that is bonded to two carbon atoms or to a CH3 group that is attached to a carbon atom may optionally carrying in each of the CH2 or CH3 groups a substituent selected from hydroxy, amino, C? -6 alkoxy, C? -6 N-alkylamino, N, N- (C? -6) alkyl, and heterocyclyl; R 2 is hydrogen, halo, Ci-β alkyl, C 2-6 alkenyl or C 2-6 alkynyl; R3 is hydrogen, halo, C6_6 alkyl, C2_6 alkenyl or C2_6 alkynyl; R 4 is hydrogen, hydroxy, C 6 alkyl, alkoxy
- C? -6, amino, N-alkylamino of Ci-e, N, N- (C? -6-alkyl) 2-amino, C2-6 hydroxyalkoxy, C? -6 alkoxy of C2-e alkoxy, aminoalkoxy of C2_6, N-C2-6 alkylamino of C2-6alkoxy, N, N- (C6-6alkyl) 2-aminoalkoxy of C2-6 or cycloalkyl of C3-7, or R4 is of the Formula (IC) : -K-J (IC) wherein J is aryl, heteroaryl or heterocyclyl and K is a bond, oxy, imino, N- (Ci-d) imino alkyl, C? -6 oxyalkylene, C? -iminoalkylene. 6, N- (C? -6 alkyl) iminoalkylene of C? -6, -? HC (O) -, -S02? H-, -? HS02- or -? HC (0) -alkylene of C? - 6-, and any aryl, heteroaryl or heterocyclyl group in a R4 group can be optionally substituted by one or more groups selected from hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulfamoyl, alkyl of C? -6, C2-6 alkenyl, C? -6 alkynyl, Ci-e alkoxy, -0- (C? _3 alkyl) -0-, C? -6 S (0) n alkyl - (where n is 0-2), N-alkylamino of C? -6, N, N- (C? -6 alkyl) 2-amino , Ci-e alkoxycarbonyl, N-alkylcarbamoyl of C? -6, N, N- (Ci-β) alkylcarbamoyl, C? -6 alkanoyl, alkanoyloxy
- C? -6, C? -6-alkanoylamino, N-alkylsulfamoyl of C? _6, N, N- (Ci-β) alkyl sulfamoyl, C? -6 alkylsulfonylamino and C? -6-N- alkylsulfonyl ( C? _6) amino alkyl, or any aryl, heteroaryl or heterocyclyl group in a R4 group may be optionally substituted with one or more groups of Formula (IA '): -B CHzJp-A1 (IA *) wherein A1 is halo , hydroxy, C? -6 alkoxy, cyano, amino, N-alkylamino of Ci-β, N, N- (C? -6 alkyl) 2-amino, carboxy, C? -6 alkoxycarbonyl, carbamoyl, N-alkylcarbamoyl of C? _6 or N, N- (Ci-e) 2-carbamoyl alkyl, p is 1-6, and B1 is a bond, oxy, imino, N- (Ci-6 alkyl) imino or -NHC (O) -, with the proviso that p is 2 or more unless B1 is a bond or -NHC (O) -, or any aryl, heteroaryl or heterocyclyl group in a R4 group can be optionally substituted with one or more groups of the Formula (IB '): E ^ D1 (IB') where D1 is aryl, heteroaryl or heterocyclyl and E1 is a bond, C? -6 alkylene, C? Oxyalkylene 6, oxy, imino, N- (Ci-e alkyl) imino, C? -6-iminoalkylene, N- (C? -6-alkyl) -iminoalkylene of C? _6, C? _6-oxyalkylene alkylene of C ? -6, C? _6-iminoalkylene alkylene of C? _6, C? -6-N- (C? -e) -iminoalkylene alkylene of C? _6,
- -? HC (O) -, -? HS02-, -S02? H- or -? HC (O) -alkylene of C? -6-, and any aryl, heteroaryl or heterocyclyl group in a substituent on R4 can optionally be substituted with one or more groups selected from hydroxy, halo, C? -6 alkyl, C? -6 alkoxy, carboxy, C? _6 alkoxycarbonyl, carbamoyl, C? -6 N-alkylcarbamoyl, N- (alkyl) of Ci-β) 2carbamoyl, C2_6 alkanoyl, amino, N-alkylamino of C? -6 and N, N- (C? -6-alkyl) 2-amino, and any cycloalkyl group of C3-7 or heterocyclyl in a group R4 it may be optionally substituted with one or two oxo or thioxo substituents, and any of the groups R4 defined above comprising a CH2 group that binds to two carbon atoms or a CH3 group that binds to a carbon atom may optionally carry about each CH2 or CH3 group a substituent selected from hydroxy, amino, C? -6 alkoxy, C? -6 N-alkylamino, N, N- (C? -6-alkyl) 2-amino and heterocyclyl; R5 is hydrogen, halo, trifluoromethyl, cyano, nitro, amino, hydroxy, C? -6 alkyl, C2-6 alkenyl, C2_6 alkynyl, C? _6 alkoxy, C? -6 N or N-alkylamino, N- (C? -6) 2amino alkyl; q is O, 1, 2, 3 or 4; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof; with the proviso that 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-dipyrimidine] is excluded. 2. The bicyclic compound of Formula (I) according to claim 1, characterized in that: the bicyclic ring formed by fusion of the X ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolpyrimidinyl, oxazolpyrimidino, thiazolopyrimidinyl, purinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl; m is 0 or m is 1 and each R1 is independently hydroxy, halo, C6-6 alkyl, C6-6 alkoxy, C6-6S (0) n- alkyl (where n is 0-2), N , N- (Ci-β) alkyl 2-aminoalkyl of C? -6, N, N- (Ci-e alkyl) 2-carbamoylalkoxy of C? -6, N, N- (C? _6 alkyl) 2-aminoalkoxy of C? -6, alkyl of i-eS (O) 2-C6-alkoxy, N, N (C6-6 alkyl) 2 amino- N- (C6-6 alkyl) C6-6 alkylamino, N , N- (Ci-6-alkyl) 2-aminoalkylamino of C? _6-C? -6 alkyl, piperidin-1-ylalkyl of Ci-e, homopiperidin-1-ylalkyl of Ci-e, N- (C? -6) piperidin-1-ylalkyl of C? -6, N- (C? _6 alkyl) homopiperidin-1-ylalkyl of C? -6, piperazin-1-ylalkyl of C? -6, 4-alkylpiperazine of C ? -6-l-C 1-6 -alkyl, homopiperazinyl-1-ylalkyl of C? -6,4-alkylhomopiperazinyl of C? -6-l-ylalkyl of C? -6, pyrrolidinylalkoxy of C? -6, piperidinylalkoxy of C? _6, homopiperidinylalkoxy of C? -6, N- (C? _6 alkyl) pyrrolidinylalkoxy of C? _6, N- (C? -d) alkyl piperidinylalkoxy of C? _6, N- (CI-T alkyl) C6-6 homopiperidinylalkoxy, C? -6 morpholinylalkoxy, C? _6 piperazinylalkoxy, N- (C? _6 alkyl) piperazinylalkoxy of C? -6, homopiperazinylalkoxy of C? 6, N- (C6-6 alkyl) homopiperazinylalkoxy of C6-6, pyrrolidinyloxy, N- (Ci-e alkyl) pyrrolidinyloxy, piperidinyloxy, N- (Ci-β alkyl) piperidinyloxy, homopiperidinyloxy, N- (alkyl) of Ci-e) homopiperidinyloxy, C 1 -C 6 -morphonylalkyalkylamino-C 6 alkyl, thiazolylalkoxy of C 6 -6 or pyridylalkoxy of C 6 -6; R ^ is hydrogen, C? -4 alkyl or halo; R3 is hydrogen, C1-4 alkyl or halo; q is 0; R 4 is phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by one or two of halo, trifluoromethyl, cyano, C ?- alkyl, C? -4 alco alkoxy, -O- (C?-Alkyl) 3) -0-, N, N- (alkyl of
- C? _4) 2-amino, C? _6 alkanoylamino, C? _6-N- (Ci_e alkyl) amino alkylsulfonyl, phenyl (optionally substituted by one or two halo groups), furyl, azetidinyl, pyrrolidinyl, 3-pyrrolinyl, piperidino, homopiperidinyl, morpholino, piperazinyl, homopiperazinyl, N- (
- C? -6) piperazinyl and N- (Ci-β alkyl) homopiperazinyl, or R4 is fluorenyl or dibenzofuranyl; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. 3. The bicyclic compound of Formula (I) according to claim 1, characterized in that: the bicyclic ring formed by fusion of the X ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolopyrimidinyl, oxazolpyrimidinyl, thiazolopyrimidinyl, purinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl; m is 0 or m is 1 and each R 1 is independently hydroxy, halo, C 1-6 alkyl, C 1-6 alkoxy, C? -6S alkyl (0) n- (where n is 0-2), N, N- (C? _6) -aminoalkyl of C? -6, N, N- (C? -6 alkyl) 2-carbamoylalkoxy of C? -6, N, N- (C? _6 alkyl) 2-aminoalkoxy of C? _6, C C-C6-alkyl (O) 2-C alco-C6-alkoxy, N, N- (C?-6-alkyl) 2-amino- N- (Ci-e alkyl) C?-6 alkylamino, N , N- (C? _6 alkyl) 2-aminoalkylamino of C? _6-C? -6 alkyl, piperazin-1-ylalkyl of C? -6, 4-alkylpiperazin of C? -6-l-ylalkyl of C? 6, Ci-e homopiperazinyl-1-ylalkyl of C? -6, 4-alkylhomopiperazinyl of C? -6-l-ylalkyl of Ci-e, pyrrolidinylalkoxy of C? -6, piperidinylalkoxy of C? -6, N- (C-alkyl) ? 6) pyrrolidinylalkoxy of C? -6, N- (alkyl of
- Ci-e) C? -6 piperidinylalkoxy, C? -6 morpholinylalkoxy, C? _6 piperazinylalkoxy, C? -6 N- (C? -6 alkyl) piperazinylalkoxy, C? -6 homopiperazinylalkoxy, N-? (C? -6 alkyl) C? -6 homopiperazinylalkoxy, pyrrolidinyloxy, piperidinyloxy, C? -6-C? -6-alkyl-C6-6 alkyl or C? -6 pyridylalkoxy, "R2 is hydrogen, C1-4 alkyl or halo, R 3 is hydrogen, C 1-4 alkyl or halo, q is 0, R 4 is phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by one or two halo, cyano, C? 4, C 1 -4 alkoxy, N, N- (C 4 -4) alkylamino, piperidinyl, morpholino or piperazinyl, and R 5 is hydrogen, or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. bicyclic compound of Formula (I) characterized in that: the bicyclic ring formed by fusion of the X ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is furo [3,2-d] pirim idinyl, furo [2, 3-d] pyrimidinyl, thieno [3,2-d] pyrimidinyl, thieno [2,3-d] pyrimidinyl, pyrrol [3,2-d] pyrimidinyl, pyrrole [2, 3-d] pyrimidinyl, oxazole [5,4-d] pyrimidinyl, oxazole [4, 5-d] pyrimidinyl, thiazole [5,4-d] pyrimidinyl, thiazole [4, 5-d] pyrimidinyl, purinyl, pyrido [2, 3] d] pyrimidinyl, pyrido [3,4-d] pyrimidinyl, pyrido [4, 3-d] pyrimidinyl, pyrido [3,2-d] pyrimidinyl, pyrimido [4, 5-d] pyrimidinyl, pyrimido [5,6- d] pyrimidinyl or pteridinyl; m is 0 or m is 1 and each R 1 is independently methyl, methoxy, methylthio, 2-diisopropylaminoethoxy, 3-diethylaminopropoxy, 3-morpholinopropoxy or 3-pyrrolidin-1-ylpropoxy; R2 is hydrogen, methyl, fluoro or chloro; R3 is hydrogen; q is 0; R 4 is phenyl optionally substituted by one or two groups selected from fluoro, chloro, trifluoromethyl, cyano, methyl, methoxy, ethoxy, methylenedioxy, N, N-dimethylamino, acetamido, N-methylmethanesulfonamido, phenyl, 4-fluorophenyl, 4- chlorophenyl, 2-furyl, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4- methylpiperazin-1-yl and 4-methylhomopiperazin-1-yl, or R 4 is pyridyl optionally a group substituted by N, N-di-ethylamino, N, N-diethylamino, azetidin-1-yl, pyrrolidin-1-yl, 3- pyrrolin-1-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4-methylpiperazin-1-yl or 4-methylhomopiperazin-1-yl, or R 4 is 1-fluorenyl or dibenzofuran-4-yl; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. 5. The bicyclic compound of the formula (I) according to claim 1, characterized in that: the bicyclic ring formed by fusion of the X ring to the 6-membered heteroaryl ring containing adjacent nitrogen within the formula (I) is furo [ 3, 2-d] pyrimidinyl, furo [2, 3-d] pyrimidinyl, thieno [3,2-d] pyrimidinyl, thieno [2, 3 d] pyrimidinyl, pyrrol [3,2-d] pyrimidinyl, pyrrole [2] , 3-d] pyrimidinyl, oxazole [5, 4-d] pyrimidinyl, oxazole [4,5-dlpyrimidinyl, thiazole [5, 4-d] pyrimidinyl, thiazole [4,5-d] pyrimidinyl, purinyl, pyrido [2 , 3-d] pyrimidinyl, pyrido [3,4-d] pyrimidinyl, pyrido [4, 3-d] pyrimidinyl, pyrido [3,2- d] pyrimidinyl, pyrimido [4,5-d] pyrimidinyl, pyrimido [5] , 6-d] pyrimidinyl or pteridinyl; m is 0 or m is 1 and each R 1 is independently methyl, methoxy, methylthio, 2-diisopropylaminoethoxy, 3-diethylaminopropoxy, 3-morpholinopropoxy or 3-pyrrolidin-1-ylpropoxy; R2 is hydrogen, methyl, fluoro or chloro; R3 is hydrogen; q is 0; R 4 is pyridyl, a group optionally substituted by an N, N-dimethylamino, N, N-diethylamino, pyrrolidin-1-yl, piperidino or morpholino; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. 6. The bicyclic compound of Formula (I) according to claim 1, characterized in that: the bicyclic ring formed by fusion of the X ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is thien [ 3, 2-d] pyrimidin-4-yl, thieno [2,3-d] pyrimidin-4-yl, thiazol [5, 4-d] pyrimidin-7-yl, 6-purinyl, pyrido [2, 3- d] pyrimidin-4-yl, pyrido [3,4-d] pyrimidin-4-yl, pyrido [4, 3-d] pyrimidin-4-yl, pyrido [3,2-d] pyrimidin-4-yl or pteridin-4-yl; m is 0 or m is 1 and R1 is methyl or methylthio; R2 is methyl; R3 is hydrogen; q is 0; R 4 is phenyl, 3-fluorophenyl, 4-cyanophenyl, 2-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-ethoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 3- (N, N-dimethylamino) phenyl , 3-acetamidophenyl, 3- (4-fluorophenyl) phenyl, 3- (2-furyl) phenyl, 3-pyrrolidin-1-ylphenyl, 3-morpholinophenyl, 3-fluoro-5-pyrrolidin-1-ylphenyl, 3-fluoro -5-piperidinophenyl, 3-fluoro-5-morpholinophenyl or 3-morpholino-5-trifluoromethylphenyl, or R4 is 2-morpholinopyrid-4-yl, or R4 is 1-fluorenyl or dibenzofuran-4-yl; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. 7. The bicyclic compound of Formula (I) according to claim 1, characterized in that: the bicyclic ring formed by fusion of the X ring to the 6-membered heteroaryl ring containing adjacent nitrogen within Formula (I) is thien [ 3, 2-d] pyrimidin-4-yl, thieno [2,3-d] pyrimidin-4-yl, thiazol [5, 4-d] pyrimidin-7-yl, pyrido [2, 3-d] pyrimidin-4-yl, pyrido [3, -d] pyrimidin-4-yl, pyrido [4, 3-d] pyrimidin-4-yl, pyrido [3,2-d] pyrimidin-4-yl or pteridin-4 -ilo; m is 0 or m is 1 and R1 is methyl or methylthio; R2 is methyl; R3 is hydrogen; q is 0; R 4 is 2-morpholinopyrid-4-yl; and R5 is hydrogen; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. 8. The bicyclic compound of the formula (I) according to claim 1, characterized in that it is selected from: - 4- [2-methyl-5- (2-morpholinopyridine-4-carboxamido) ani-lino] thieno [3, 2-d] pyrimidine, 4- [2-methyl-5- (2-morpholinopyridin-4-carboxamido) anilino] pyrido [4, 3-d] pyrimidine, 4- [2-methyl-5- (2-morpholinopyridine-4-carboxamido) anilino] pteridine and 6- [2-methyl-5- (2-morpholinopyridine-4-carboxamido) anilino] -purine; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof. 9. The process for preparing a compound of the Formula (I), or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof, according to claim 1, characterized in that it comprises: a) reacting an aniline of the Formula ( II): with an acyl compound of Formula (III) OX "XCH2) and q" (III) wherein G, R1, R2, R3, R4, R5, ring X, myq is a displaceable group as defined in claim 1 and L is a displaceable group; b) reacting an activated bicyclic heteroaryl ring of Formula (IV): wherein G, R1, the X and m ring as defined in claim 1, wherein L is a displaceable group with an aniline of the Formula (V):
- (V) wherein R2, R3, R4, R5 and q are as defined in claim 1; or c) for the preparation of a compound of the
- Formula (I) wherein R1 or a substituent on R4 is C6-6 alkoxy or substituted C6-6 alkoxy, Ci-ßS- alkyl, N-alkylamino of C? -6, N, N- ( C? -6) 2amino alkyl or substituted C? -6 alkylamino, the alkylation, conveniently in the presence of a suitable base, of a compound of the Formula
- (I) wherein R1 or a substituent on R4 is hydroxy, mercapto or amino as appropriate; and after that if necessary: i) converting a compound of the Formula (I) to another compound of the Formula (I); ii) remove any protective group; and iii) forming a pharmaceutically acceptable salt or ester cleavable in vivo. 10. The pharmaceutical composition characterized in that it comprises a bicyclic compound of the formula (I), or an acceptable pharmaceutical salt or in vivo cleavable ester thereof, according to claim 1, in association with an acceptable pharmaceutical carrier or diluent. 11. The use of a bicyclic compound of the Formula (I) or an acceptable pharmaceutical salt or an in vivo cleavable ester thereof, according to claim 1, or the use of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine in the manufacture of a medicament for use in the treatment of diseases or medical conditions mediated by cytokines.
- 12. A method for treating diseases or medical conditions mediated by cytokines characterized in that it comprises administering to a warm-blooded animal an effective amount of a bicyclic compound of the Formula (I), or an acceptable pharmaceutical salt or an in vivo cleavable ester thereof, according to claim 1 or of the compound 7-amino-4- (3-acetamidoanilino) pyrido [4, 3-d] pyrimidine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9906566.6 | 1999-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA01009502A true MXPA01009502A (en) | 2002-06-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1165566B1 (en) | Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease | |
AU761552B2 (en) | Chemical compounds | |
EP1226126B1 (en) | Pyrimidine derivatives | |
SK3542002A3 (en) | Pteridinones as kinase inhibitors | |
US20080008720A1 (en) | Substituted Tricyclic Heterocycles and their Uses | |
JP2008505084A (en) | Furanopyrimidine | |
MXPA01012887A (en) | Quinazoline derivatives. | |
AU2006227297A1 (en) | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | |
MXPA01009502A (en) | Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease | |
CN110612302B (en) | Pyrazolo [1,5-a ] pyrimidine derivatives as kinase JAK inhibitors | |
MXPA01003424A (en) | Chemical compounds | |
WO2023185073A1 (en) | Parp7 inhibitor and use thereof | |
MXPA01009308A (en) | Amide derivatives |